SCODiA Report by MLBI Lab

Single-Cell Resolution of Cellular Heterogeneity, Genomic Instability, and Immunosuppressive Microenvironment Remodeling in Human Lung Cancer Progression

This comprehensive single-cell analysis of human lung tissue reveals the intricate landscape of lung cancer progression. Malignant lung epithelial cells, characterized by pervasive aneuploidy and activated oncogenic pathways, drive tumor growth and extensively remodel the tumor microenvironment. Key findings highlight dynamic shifts in immune cell populations, particularly the early and sustained enrichment of immunosuppressive regulatory T cells and pro-tumorigenic M2-like macrophages. Altered cell-cell communication networks, involving prominent EGFR, TGF-beta, and immune checkpoint signaling, contribute to immune evasion, angiogenesis, and stromal support, offering critical insights for therapeutic intervention.

Contents

0. Dataset overview
1. UMAP Visualization of Lung Cancer Single-Cell Data
2. Major Cell Type Score and Ploidy Analysis on UMAP
3. Marker Expression Dot Plot for Cell Subtypes in Lung Tissue
4. Copy Number Variation (CNV) Analysis in Tumor-Origin Lung Epithelial Cells
5. UMAP Visualization of CNV Patterns by Cell Type, Ploidy, Condition, and Sample
6. Cell Type Population Analysis by Disease Condition in Lung Tissue
7. T Cell Subset Population Dynamics in Lung Cancer Progression
8. Differential Abundance of T Cell Subsets and ILC2s in Lung Cancer Progression
9. Macrophage Subpopulation Shifts Across Lung Cancer Stages
10. Macrophage Subset Population Shifts Across Lung Cancer Progression
11. Ploidy Analysis of Tumor-Origin Lung Epithelial Cells
12. Cell-Cell Interaction Patterns in Lung Cancer Microenvironment
13. Condition-Specific Cell-Cell Interaction Patterns in Lung Cancer
14. Condition-Specific Cell-Cell Interaction Patterns in Lung Cancer
15. Surfaceome Marker Expression in Lung Epithelial Cells of Lung Cancer
16. Macrophage Condition-Specific Surfaceome Markers in Lung Cancer
17. Fibroblast Condition-Specific Surfaceome Markers in Lung Cancer
18. Condition-Specific Surfaceome Markers in CD4+ T Cells in Lung Cancer
19. Differential Expression of Cell Cycle Genes in Lung Epithelial Cells Across Lung Cancer Stages
20. Gene Ontology Analysis of Lung Epithelial Cells Across Conditions
21. Gene Set Enrichment Analysis of Lung Cancer Microenvironment
22. Discussion
23. Query List

0. Dataset overview

Dataset Summary

• Dimensions: 84,300 cells and 23,489 genes.
• Species & Tissue: Human, Lung tissue.
• Conditions: Includes 'Tumor(adv)', 'Tumor(early)', and 'Normal' conditions.
• Cell Types: Contains hierarchical cell type annotations: 'celltype_major', 'celltype_minor', and 'celltype_subset'.
  • Major Cell Types: T cell, Lung Epithelial cell, Myeloid cell, B cell, Mast cell, Stromal cell, unassigned, Endothelial cell.
  • Minor Cell Types: T cell CD8+, T cell CD4+, Alveolar Epithelial cell, Macrophage, Plasma cell, Mast cell, ILC, Fibroblast, Dendritic cell, Airway Epithelial cell, B cell, NK cell, unassigned, Smooth muscle cell, Endothelial cell.
  • Subset Cell Types: Detailed subtypes like T cell (Cytotoxic), Macrophage (M2B), Alveolar type 2, etc.
• Ploidy Information: Observed ploidy labels include Diploid (88.4%) and Aneuploid (11.6%).
• Tumor Context: Tumor identification is confirmed. 'Lung Epithelial cell' is resolved as the tumor-origin cell type.
• Metadata: Rich metadata available in 'obs' columns, including Patient id, Tissue origins, Histology, Gender, Age, Smoking, Pathology, EGFR_mutation, Stage, and various cell-level metrics and annotations.
• CNV Data: Copy Number Variation (CNV) estimates are available.
• Precomputed Results: The dataset includes precomputed results for Cell-Cell Interaction (CCI), Differential Expression Genes (DEG), Gene Set Enrichment Analysis (GSEA), and Gene Ontology (GSA/GO) analyses, available both per condition and against a 'Normal' reference condition.

Inferred Disease/Biological Context

• The dataset strongly indicates a focus on Lung Cancer due to explicit 'Tumor' conditions, the identification of 'Lung Epithelial cell' as the tumor-origin, and the presence of cancer-related metadata such as 'Histology', 'Pathology', 'EGFR_mutation', and 'Stage'.

1. UMAP Visualization of Lung Cancer Single-Cell Data

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots, an unsupervised dimensionality reduction technique, to visualize the global cellular heterogeneity of single-cell RNA-sequencing data from human lung tissue. The UMAPs are colored by various metadata attributes including condition (Normal, Tumor(early), Tumor(adv)), sample identifier, celltype_major, celltype_minor, ploidy_dec (Aneuploid, Diploid, Unclear), and celltype_subset. The purpose of these visualizations is to assess the quality of the cell embeddings, evaluate the consistency of cell type annotations, investigate the distribution of different conditions and samples, and identify populations based on their ploidy status within the complex tissue microenvironment of Lung Cancer.

Visual Summary

1. Condition UMAP

The UMAP colored by condition displays a noticeable separation between Normal cells (dark red) and cells from Tumor(adv) (yellow) and Tumor(early) (purple) samples. Normal cells predominantly occupy distinct clusters, suggesting unique transcriptional profiles. Tumor(adv) and Tumor(early) cells show areas of intermingling, indicating some shared cellular states, but also form distinct clusters, hinting at specific gene expression programs associated with disease progression stages.

2. Sample UMAP

The sample UMAP reveals a high degree of sample-specific clustering, with many individual samples forming discrete groupings. This indicates either strong patient-specific biological variation or potential technical batch effects. However, several clusters exhibit a mix of multiple samples, suggesting the presence of shared cell types or conditions across different patient samples.

3. Celltype Major UMAP

Clear segregation of major cell types is observed. T cell (cyan/blue) populations form a large, distinct cluster, while Myeloid cell (light green), Lung Epithelial cell (orange), Stromal cell (teal), B cell (dark red), and Mast cell (yellow) each occupy well-defined regions. Lung Epithelial cell populations appear in several distinct clusters, including regions that overlap with cells identified as Tumor(adv) and Aneuploid in other plots.

4. Celltype Minor UMAP

At a finer resolution, the celltype_minor UMAP further refines the major cell types. T cell CD8+ (blue) and T cell CD4+ (dark blue) are distinct but remain interconnected. Other populations like Macrophage (yellow), Dendritic cell (orange), Alveolar Epithelial cell (dark red), and Airway Epithelial cell (red) also form well-demarcated clusters, demonstrating the robust resolution of these populations.

5. Ploidy_dec UMAP

The ploidy_dec UMAP is particularly informative, showing that Aneuploid cells (dark red) are largely confined to specific, distinct clusters. These clusters visually correspond to regions enriched for Tumor(adv) and Lung Epithelial cell populations. Diploid cells (yellow) are broadly distributed across most of the UMAP landscape, as expected for healthy and non-malignant cells. The Unclear cells (purple) are very few and sparsely distributed, indicating high confidence in the ploidy assignments for the vast majority of cells.

6. Celltype Subset UMAP

The celltype_subset UMAP provides the most granular view of cellular heterogeneity. It resolves numerous fine-grained populations such as Alveolar type 2 (AT2, dark red), Alveolar type 1 (AT1, red), diverse Macrophage subtypes (e.g., Mac_M1, Mac_M2a, Mac_M2b), and various T cell subsets (e.g., T_Cyto, T_Naive, Tfh, Treg). These highly resolved populations underscore the extensive cellular complexity within the lung tissue and tumor microenvironment.

Biological Interpretation

• Tumor-Specific Signatures and Progression: The distinct clustering of cells by condition highlights significant transcriptional divergence between normal lung tissue and both early and advanced stages of lung cancer. This suggests that the tumor microenvironment undergoes substantial remodeling and that distinct molecular programs drive disease progression, which could be explored in subsequent differential expression and pathway analyses.
• Identification of Malignant Cells: The strong co-localization of Aneuploid cells with specific clusters, particularly those identified as Lung Epithelial cell and associated with Tumor(adv)/Tumor(early) conditions, provides compelling evidence for the successful identification of malignant cells. This aligns with the 'Resolved tumor-origin cell type' being Lung Epithelial cell, strongly supporting that these aneuploid epithelial populations represent the cancerous cells.
• Heterogeneous Tumor Microenvironment: The detailed celltype_minor and celltype_subset UMAPs reveal the rich cellular diversity within the lung, including various immune cells (T cells, B cells, macrophages, dendritic cells) and stromal components (fibroblasts, endothelial cells). The spatial distribution of these cell types relative to the tumor clusters is critical for understanding immune evasion mechanisms, pro-tumorigenic stroma, and potential therapeutic vulnerabilities in the tumor microenvironment. For instance, specific macrophage polarization states (e.g., Mac_M2a/b/c/d) or T cell subsets (e.g., Treg, T_Cyto) might exhibit distinct distributions in tumor versus normal regions, reflecting their functional roles in the disease.

Annotation Notes

• Robust Cell Type Annotation: The clear separation and distinct clustering of cells across all hierarchical levels of annotation (celltype_major, celltype_minor, celltype_subset) demonstrate the high quality and reliability of the cell type assignments in this dataset. This provides a strong foundation for in-depth cell-type-specific analyses.
• Effective Ploidy Discrimination: The ploidy_dec UMAP, showing distinct clusters for Aneuploid and Diploid cells with a minimal Unclear population, indicates that the ploidy inference method effectively distinguishes malignant cells from normal counterparts. This is a valuable feature for isolating and studying tumor cells directly from the single-cell data.
• Sample Variability Consideration: While biological signals are clearly captured, the visible sample-specific clustering in the sample UMAP suggests that sample-to-sample variability or potential batch effects might need careful consideration in downstream quantitative comparisons. However, the consistent clustering of cell types and conditions across this variability indicates that the underlying biological signals are robust.

2. Major Cell Type Score and Ploidy Analysis on UMAP

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell types and ploidy status across the single-cell RNA-seq dataset using Uniform Manifold Approximation and Projection (UMAP). The primary objective is to assess the quality of cell type annotations by examining cell type-specific scores on the UMAP embedding and to determine the spatial relationship between annotated cell types and chromosomal aneuploidy.

Visual Summary

The provided UMAP plots display the major cell type scores (HiCAT_major_score) for T cells, B cells, Myeloid cells, Mast cells, Endothelial cells, Stromal cells, and Lung Epithelial cells. These are shown alongside plots colored by ploidy status (ploidy_dec) and the assigned major cell type (celltype_major).

1. Cell Type Score Distribution: Each HiCAT_major_score plot clearly delineates regions of high score (indicated by yellow/green color) corresponding to distinct clusters on the UMAP. For example, high T cell scores are concentrated in the large left-central and upper-left clusters, while high Myeloid cell scores are seen in the right-central region. Lung Epithelial cell scores are particularly high in the upper-right quadrant, indicating a distinct population.
2. Ploidy Status Distribution: The ploidy_dec plot highlights a prominent population of aneuploid cells (red) predominantly located in the upper-right region of the UMAP. The vast majority of other cells are diploid (light yellow), with a negligible number classified as "Unclear."
3. Major Cell Type Annotation: The celltype_major plot shows the manually assigned major cell types, with distinct colors for each type. These clusters largely align with the regions of high scores observed in the individual HiCAT_major_score plots. For instance, the T cell cluster in celltype_major corresponds directly to the high T cell score region. Crucially, the Lung Epithelial cell cluster (light orange) in the upper-right region directly overlaps with the aneuploid cell population shown in the ploidy_dec plot.

Biological Interpretation

The UMAP visualizations provide compelling insights into the cellular composition and disease-relevant characteristics of the lung tissue sample:

• Robust Cell Type Identification: The strong concordance between the HiCAT_major_score plots and the celltype_major annotations demonstrates a high quality of cell type assignment. Each major cell type forms distinct, well-separated clusters, indicating effective dimensionality reduction and clustering. This provides confidence in the cellular identities used for downstream analyses.
• Tumor Cell Identification: A critical finding is the clear co-localization of aneuploid cells (red in ploidy_dec) with the Lung Epithelial cell population (light orange in celltype_major and high score in HiCAT_major_score: Lung Epithelial cell). This is highly significant in the context of Lung Cancer, as lung epithelial cells are the resolved tumor-origin cell type, and aneuploidy is a hallmark of malignancy. This observation strongly suggests that the identified aneuploid Lung Epithelial cells represent the malignant cell population within the tumor.
• Tumor Microenvironment Composition: The presence of distinct clusters of various immune cells (T cells, B cells, Myeloid cells, Mast cells) and stromal cells (Endothelial cells, Stromal cells) indicates a complex tumor microenvironment. These populations are clearly segregated from the likely malignant epithelial cells, suggesting distinct biological roles and spatial organization within the tissue.

Annotation Notes

• The consistency between the cell type scoring and the final celltype_major annotations is excellent, validating the robustness of the cell type assignments.
• The presence of a minor 'unassigned' cluster, which shows low scores across all major cell type score plots, suggests that the majority of cells have been confidently annotated. Further investigation might be needed for these 'unassigned' cells if they represent a biologically interesting population.
• The clear spatial separation of various cell types on the UMAP further supports the quality of the embedding and clustering, minimizing potential annotation ambiguities due to overlapping populations.

3. Marker Expression Dot Plot for Cell Subtypes in Lung Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a marker expression dot plot for various celltype_subset populations identified in the single-cell RNA-seq dataset from human lung tissue. The plot visualizes both the mean expression level (color intensity, ranging from white to dark red) and the fraction of cells expressing a given gene (dot size) for a curated set of marker genes. The purpose of this plot is to assess the specificity and robustness of the celltype_subset annotations by examining the expression patterns of known and discovered marker genes, ensuring that each cluster exhibits distinct and appropriate transcriptional signatures. The analysis applies a var_group_rotation of 45 degrees for readability, and target_cell was set to None to display markers for all identified celltype_subset populations.

Visual Summary

The dot plot effectively visualizes marker gene expression across 37 distinct celltype_subset populations. Each row represents a celltype_subset, and each column represents a marker gene. Genes are grouped along the x-axis, with red rectangular boxes highlighting sets of genes highly specific to certain cell type groups.

• Distinct Expression Patterns: Most celltype_subset populations show clear and distinct marker gene expression. Highly specific markers are visible as large, dark red circles concentrated within specific rows.
• Cell Type Grouping by Markers: The x-axis gene grouping (marked by horizontal red brackets) largely corresponds to the y-axis cell type grouping, indicating that the identified markers are effective in discriminating between the different celltype_subset populations.
• Expression Intensity and Prevalence: The plot reveals not only which genes are expressed but also *how strongly* (color intensity) and in *what proportion* of cells (dot size) within each group. For instance, genes like *SFTPC* in Alveolar type 2 cells show both high expression and high prevalence.
• Underlying Cell Counts: The rightmost column indicates the number of cells belonging to each celltype_subset, providing context for the robustness of marker identification for each group. T cell (Cytotoxic) has the largest population (14806 cells), followed by Alveolar type 2 (8538 cells).

Biological Interpretation

The marker expression patterns generally provide strong support for the assigned celltype_subset annotations, consistent with known cell biology in lung tissue and the context of Lung Cancer.

Lung Epithelial Cells

• Alveolar type 1 cells show high expression of *HOPX* and *EMP2* (GeneCards: HOPX, EMP2), which are characteristic markers for squamous alveolar cells.
• Alveolar type 2 cells are clearly identified by the expression of surfactant-associated proteins such as *SFTPC*, *SFTPA1*, *SFTPA2*, and *SFTPB*, along with *NAPSA* (GeneCards: SFTPC). This is crucial given that "Lung Epithelial cell" is the resolved tumor-origin cell type, and AT2 cells are progenitors often implicated in lung adenocarcinoma.
• Basal cells express classic markers *KRT5* and *KRT15* (GeneCards: KRT5), consistent with their role as progenitors in the airway epithelium.
• Ciliated cells show strong expression of *FOXJ1* (GeneCards: FOXJ1) and genes associated with ciliary function like *DNAH12*.
• Goblet cells show some expression of *MUC1*.
• Secretory club cells are marked by *SCGB3A1* and *SCGB1A1*, characteristic of these bronchiole-resident cells (GeneCards: SCGB3A1).

Immune Cells

• B cells (Breg and MZ) show expression of *POU2F2* (OCT2), a transcription factor important in B cell development and function. However, the presence of *KRT17* in B cell (MZ) is atypical, as keratins are primarily epithelial markers.
• Dendritic cells (Classical, Inflammatory, Plasmacytoid) express characteristic markers such as *CD83*, *CD86*, and *CD1A* for classical/inflammatory subsets, and *LILRA4* (CD85g) for plasmacytoid DCs (GeneCards: LILRA4).
• Macrophages (M1, M2A, M2B, M2C, M2D) are broadly identified by *MSR1* and *A2M*, with some variation across M2 subtypes. *MSR1* (Macrophage Scavenger Receptor 1) is often associated with macrophage function (GeneCards: MSR1).
• Mast cells are distinctly marked by *TPSAB1* (Tryptase Alpha/Beta 1) and *GATA2* (GeneCards: TPSAB1).
• NK cells and ILC1 share expression of *KLRD1* (CD94), a marker for NK cells and certain ILC subsets (GeneCards: KLRD1).
• Plasma cells exhibit strong and specific expression of *JCHAIN*, *XBP1*, and *MZB1*, consistent with their role in antibody production (GeneCards: JCHAIN).
• T cells (Cytotoxic, Th17, Th2, Treg) show specific markers such as *GATA3* for T cell (Th2) and *TNFRSF18* (GITR) for T cell (Treg). *IL2RG* (common gamma chain) is found in T cell (Th17), which is broadly expressed in lymphocytes. *CD69*, *CD7*, *CD44* are general T cell activation/memory markers.

Stromal and Endothelial Cells

• Fibroblasts show a clear signature with genes like *DCN*, *LUM*, *COL1A1*, and *COL3A1*, reflecting their extracellular matrix production role (GeneCards: DCN).
• Lymphatic Endothelial cells are well-defined by *PROX1* and *PDPN* (GeneCards: PROX1), which are key markers for lymphatic endothelial cell identity.
• Smooth muscle cells display robust expression of genes like *ACTA2* (alpha-smooth muscle actin), *MYH11*, and *TAGLN*, indicative of their contractile function (GeneCards: ACTA2).

Annotation Notes and Potential Refinements

The dot plot generally confirms the high quality of the celltype_subset annotations, with most cell types exhibiting distinct and biologically plausible marker gene expression profiles. The use of multiple specific markers for each subtype enhances confidence in the assignments.

However, a notable observation that warrants further investigation is the expression of *KRT17* in B cell (MZ). Keratin 17 is typically an intermediate filament protein expressed in epithelial cells, particularly in basal cells or certain proliferative epithelial states. Its expression in a B cell population could indicate a potential misannotation, a unique biological state (e.g., interaction with transformed epithelial cells leading to aberrant gene expression, or a rare cell state), or a technical artifact. This specific annotation could benefit from cross-referencing with additional B cell-specific markers not shown, or by re-evaluating the clustering of these specific B cells. Otherwise, the identified markers robustly support the existing cell type subset annotations.

4. Copy Number Variation (CNV) Analysis in Tumor-Origin Lung Epithelial Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates copy number variations (CNVs) specifically within Lung Epithelial cells identified as tumor-origin, derived from single-cell RNA-seq data. The primary goal is to visualize the genomic landscape of CNVs across different samples and to identify recurrent regions of amplification. The results are presented as a heatmap illustrating log2(Copy Number Ratio) across genomic spots, grouped by sample, alongside a summary table and bar plot detailing significantly amplified cytogenetic bands and their frequencies. This analysis is crucial for understanding the genomic instability characteristic of lung cancer and for identifying potential oncogenic drivers.

Visual Summary

Figure 1: CNV Heatmap of Lung Epithelial Cells by Sample

The heatmap displays the log2(Copy Number Ratio) for Lung Epithelial cells, organized by genomic spot (chromosomes 1-22) on the x-axis and individual samples on the y-axis.

• Ploidy Validation: Samples prefixed with "Diploid\_" (e.g., Diploid_BRONCHO_58, Diploid_LUNG_T06) exhibit largely neutral copy number profiles (white/yellowish tones), validating their classification as diploid cells. This indicates a stable genomic background for these presumed non-tumor or normal cells.
• Tumor-Associated CNVs: In stark contrast, numerous samples (e.g., LUNG_T06, LUNG_T18, LUNG_T19, LUNG_T20, LUNG_T25, LUNG_T28, LUNG_T30, LUNG_T31, LUNG_T34, BRONCHO_58, EBUS_06, EBUS_28, EBUS_49) show extensive and complex patterns of genomic alterations. Red and yellow regions indicate copy number amplifications (log2(CNR) > 0), while blue regions indicate deletions (log2(CNR) < 0). This genomic instability is a hallmark of cancer.
• Recurrent Alterations: Several chromosomal regions display recurrent amplifications across multiple tumor-associated samples. Notably, there are prominent amplifications on chromosome 7 (around genomic spot 500-600) and chromosome 17 (around genomic spot 1100-1200), as well as on chromosome 8.

Figure 2: Summary of Significantly Amplified Cytogenetic Bands

This figure provides a detailed summary of recurrent amplification events.

• Left Panel (Heatmap): Illustrates the scaled frequency or magnitude of amplification within specific cytogenetic bands across the analyzed samples. Darker blue shades indicate higher prevalence or stronger amplification. This panel clearly highlights common amplification hotspots across samples.
• Right Panel (Bar Plot): Displays the overall frequency of amplification for each identified cytogenetic band. The most frequently amplified regions include:
  • 7p13:7q11.23 (EGFR): This region shows the highest frequency of amplification, indicating a highly recurrent event in this cohort of lung cancer samples.

1q21.3:1q23.2

• 17q21.1:17q21.2 (ERBB2): Another highly recurrent amplification.

20p11.21:20q11.23

5q31.1:5q31.3

8q24.3:8q24.3 (GSDMD)

These plots confirm the presence of significant and recurrent genomic amplifications in the tumor-origin Lung Epithelial cells.

Biological Interpretation

The CNV analysis provides strong evidence of genomic instability in the identified tumor-origin Lung Epithelial cells, consistent with the inferred Lung Cancer context. The clear distinction between diploid samples and tumor-associated samples validates the cell type and ploidy annotations.

• Oncogenic Driver Amplifications: The most striking finding is the recurrent amplification of the 7p13:7q11.23 region, which harbors the *EGFR* gene, and the 17q21.1:17q21.2 region, containing the *ERBB2* (HER2) gene. Both *EGFR* and *ERBB2* are well-established oncogenes that, when amplified or mutated, drive tumor growth and progression in various cancers, particularly in Non-Small Cell Lung Cancer (NSCLC) for *EGFR*. The observation of *EGFR* amplification aligns with the presence of EGFR_mutation metadata in the dataset context, suggesting the importance of this pathway in the analyzed tumors.
  • EGFR (Epidermal Growth Factor Receptor): A receptor tyrosine kinase involved in cell growth, proliferation, and survival. Its amplification is a known mechanism of resistance to targeted therapies or a primary driver mutation in lung cancer. GeneCards: EGFR
  • ERBB2 (HER2): Another member of the EGFR family, its amplification is a critical driver in approximately 2-4% of lung adenocarcinoma patients and is associated with aggressive disease. GeneCards: ERBB2

Other Recurrent Amplifications:

• 1q21.3:1q23.2: This region is frequently amplified in various cancers and contains genes involved in cell cycle regulation and immune response. PubMed search: 1q21.3 amplification cancer
• 8q24.3 (GSDMD): The *GSDMD* gene is involved in pyroptosis, an inflammatory form of programmed cell death. Amplification could impact cell survival and immune responses within the tumor microenvironment. GeneCards: GSDMD

• Tumor Heterogeneity: While some CNVs are recurrent, the heatmap also illustrates sample-specific CNV landscapes. This genomic heterogeneity among different patient samples (LUNG_T samples, EBUS_ samples) underscores the unique genetic alterations that can develop in individual tumors.

Clinical or Translational Implications

The identification of recurrent and significant amplifications of oncogenes like *EGFR* and *ERBB2* has direct clinical implications for lung cancer management:

• Targeted Therapy: Patients with *EGFR* amplification or specific mutations are often candidates for EGFR tyrosine kinase inhibitors (TKIs). Similarly, *ERBB2* amplified lung cancers can be targeted with HER2-directed therapies. This analysis provides molecular evidence that could guide treatment selection for these patients.
• Biomarker Identification: These recurrent amplifications serve as potential biomarkers for patient stratification, prognosis, and prediction of response to specific treatments.
• Personalized Medicine: The observed genomic heterogeneity among samples highlights the importance of comprehensive molecular profiling for each patient to enable a truly personalized medicine approach in lung cancer treatment.
• Further Research: The identification of other frequently amplified regions (e.g., 1q21.3:1q23.2, 20p11.21:20q11.23) warrants further investigation to understand their functional roles and potential as novel therapeutic targets or prognostic markers in lung cancer.

5. UMAP Visualization of CNV Patterns by Cell Type, Ploidy, Condition, and Sample

[Analysis Visualization Results]...

Analysis Overview

This analysis presents UMAP (Uniform Manifold Approximation and Projection) plots generated using CNV (Copy Number Variation) estimates. These visualizations aim to represent the cellular landscape based on genomic alterations and are colored by various cellular and sample-level metadata, including major cell types (celltype_major), minor cell types (celltype_minor), ploidy status (ploidy_dec), experimental condition (condition), and individual samples (sample). The CNV-based embedding allows for the exploration of how genomic instability structures the cell populations and relates to cell identity, disease state, and sample origin in the context of Lung Cancer.

Visual Summary

The UMAP plots reveal distinct clustering patterns driven by CNV profiles, effectively segregating different cellular populations.

• celltype_major: The UMAP shows two major regions. A large, diffuse cluster primarily encompasses immune cells (T cell, Myeloid cell) and Stromal cells (light blue, yellow, light green). A distinct, more compact cluster (orange) on the right side of the embedding is dominated by Lung Epithelial cells. Other cell types like Endothelial cells and B cells form smaller, distinct groups or are interspersed.
• celltype_minor: This plot provides a more granular view, further resolving the immune/stromal cluster into specific subtypes like T cell CD8+, T cell CD4+, Macrophage (Mac), and Fibroblast (Fib). The distinct Lung Epithelial cluster on the right is identified as primarily Alveolar Epithelial cell and Airway Epithelial cell.
• ploidy_dec: A striking observation is the clear segregation based on ploidy status. The compact cluster on the right, which corresponded to Lung Epithelial cells, is almost exclusively composed of "Aneuploid" cells (dark red/maroon). Conversely, the large, diffuse cluster on the left is overwhelmingly "Diploid" (yellow). "Unclear" cells are very rare and scattered.
• condition: This plot strongly corroborates the ploidy_dec pattern. The "Aneuploid" region is predominantly populated by cells from "Tumor(adv)" (blue) and "Tumor(early)" (yellow) conditions. The "Diploid" region largely consists of "Normal" cells (dark red/maroon), but also includes cells from "Tumor(early)" and "Tumor(adv)" conditions, indicating the presence of non-malignant cells within the tumor microenvironment.
• sample: The distribution of cells colored by sample shows that the large diploid cluster is composed of cells from various samples, suggesting a robust representation of different patients. The aneuploid tumor cluster also comprises cells from multiple tumor samples, indicating that the observed CNV-driven segregation is a consistent feature across different patients with Lung Cancer rather than a sample-specific artifact. Some sample-specific sub-clustering might be observed within both the diploid and aneuploid regions, reflecting inter-patient heterogeneity.

Biological Interpretation

The UMAP visualizations provide compelling evidence regarding the cellular and genomic landscape of the lung tissue samples, particularly in the context of Lung Cancer.

1. Tumor Cell Identification and Origin: The CNV-based embedding effectively separates malignant cells from non-malignant cells. The ploidy_dec plot clearly shows a distinct cluster of aneuploid cells, which, when cross-referenced with celltype_major and celltype_minor, is almost entirely comprised of Lung Epithelial cells. This observation strongly aligns with the pre-defined Resolved tumor-origin cell type: Lung Epithelial cell and the inferred disease context of Lung Cancer, where malignancy typically arises from epithelial cells.
2. Genomic Instability as a Primary Driver of Cell Clustering: The profound separation of cells based on ploidy_dec (aneuploid vs. diploid) confirms that CNV status is a major factor shaping the UMAP embedding. This highlights the extensive genomic instability present in tumor cells and underscores its utility in distinguishing malignant from non-malignant populations in single-cell data.
3. Tumor Microenvironment (TME) Composition: The large, diffuse diploid cluster represents the non-malignant cells of the TME, including diverse immune populations (T cells, Myeloid cells) and stromal components (Fibroblasts). These cells are found in both "Normal" and "Tumor" conditions, as expected for cells that infiltrate or reside within the tumor site but do not harbor the extensive aneuploidy characteristic of the tumor clone. The presence of non-malignant cells in tumor conditions reflects the complex ecosystem of the TME.
4. Condition-Specific Cell Distributions: The condition UMAP shows a clear enrichment of "Normal" cells in the diploid clusters, while "Tumor(early)" and "Tumor(adv)" cells are enriched in both the aneuploid (tumor epithelial) and diploid (TME) compartments. This further supports the distinct genomic profiles of tumor cells and the heterogeneous cellular composition of the tumor environment at different disease stages. The mixing of early and advanced tumor stages within the aneuploid cluster suggests that the primary CNV features captured by this embedding might be broadly shared across tumor progression, or that more subtle CNV changes between stages are not fully resolved at this level.

Annotation Notes

• The strong concordance between ploidy_dec, condition, and celltype_major/minor in identifying the tumor cell compartment provides high confidence in the accuracy of the cell type annotations and CNV estimations.
• The unassigned cells are minimal and broadly distributed, indicating a high quality of cell type annotation across the dataset.
• The embedding effectively captures biologically meaningful variation, particularly the distinction between malignant and non-malignant cells based on their CNV landscape. This provides a robust foundation for downstream analyses focusing on tumor-specific biology and interactions within the TME.

6. Cell Type Population Analysis by Disease Condition in Lung Tissue

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of different celltype_minor categories across individual samples, stratified by disease condition: Normal, Tumor (advanced), and Tumor (early). Each bar represents a single sample, with stacked segments showing the percentage contribution of each identified minor cell type. This visualization provides insights into the cellular composition shifts associated with lung cancer progression.

Visual Summary

The stacked bar plots reveal distinct differences in cell type proportions between normal lung tissue and tumor samples, and also between early and advanced tumor stages.

• Normal Samples: These samples (e.g., LUNG_N28, LUNG_N30) exhibit a relatively diverse cellular composition. Prominent cell types include T cell CD4+, T cell CD8+, Macrophage, and Alveolar Epithelial cell. Airway Epithelial cells are also present but typically constitute a smaller fraction. The "unassigned" category is minimal.
• Tumor (advanced) Samples: A striking feature of advanced tumor samples (e.g., EBUS_28, BRONCHO_58, EBUS_06) is the pronounced dominance of Alveolar Epithelial cells (dark red). In some samples, this cell type can account for up to ~90% of the total cells (e.g., EBUS_28). Airway Epithelial cells (burgundy) are also notably increased in some advanced tumor samples (e.g., EBUS_49). Correspondingly, the relative proportions of many immune cell types, such as T cells (CD4+ and CD8+) and Macrophages, appear to be proportionally reduced due to the expansion of epithelial cells.
• Tumor (early) Samples: Early tumor samples (e.g., LUNG_T34, LUNG_T08) also show an elevated proportion of Alveolar Epithelial cells compared to normal tissue, although generally less uniformly dominant than in advanced tumors. For instance, LUNG_T34 shows a significant enrichment of Alveolar Epithelial cells (~75%), while other early tumor samples have a more varied increase. Airway Epithelial cells are also noticeably present in several early tumor samples. The overall cellular diversity appears to be in an intermediate state between normal and advanced tumor samples, with immune cell populations still contributing, albeit with altered relative proportions. The "unassigned" category appears slightly more prominent in some early tumor samples compared to normal.

Biological Interpretation

The observed shifts in cell populations provide strong biological insights into lung cancer development and its impact on the tissue microenvironment.

• Epithelial Cell Proliferation as a Hallmark of Cancer: The most prominent finding is the substantial increase in Alveolar Epithelial cells and, to a lesser extent, Airway Epithelial cells in both early and advanced tumor samples. This directly correlates with the data context identifying 'Lung Epithelial cell' as the 'Resolved tumor-origin cell type'. This expansion represents the uncontrolled proliferation of malignant epithelial cells, a defining characteristic of cancer. The higher prevalence and dominance of these epithelial cells in advanced tumors suggest increased tumor burden and progression.
• Tumor Microenvironment Remodeling: The relative decrease in the proportion of immune cells (such as T cells, Macrophages, NK cells) in tumor samples, particularly advanced ones, indicates a significant remodeling of the tumor microenvironment (TME). While their *relative* percentage might be lower due to the massive expansion of tumor cells, their *absolute* numbers and functional states are crucial. This proportional shift could imply immune evasion mechanisms where tumor cells outgrow the immune surveillance, or it could reflect an altered immune cell infiltration profile.
• Progression from Early to Advanced Disease: The comparison between early and advanced tumor stages suggests a progressive increase in tumor cell dominance. Early tumors show an initial expansion of epithelial cells, which becomes more pronounced and consistent in advanced tumors. This reflects the natural history of cancer progression, where a growing mass of malignant cells gradually overtakes the normal tissue architecture. The presence of 'unassigned' cells in tumor samples, especially early ones, might represent progenitor cells, dedifferentiated tumor cells, or cells undergoing novel phenotypic changes within the evolving tumor microenvironment.

Clinical or Translational Implications

These findings have several potential clinical and translational implications for lung cancer:

• Diagnostic and Prognostic Markers: The dramatic increase in lung epithelial cells (Alveolar and Airway) could serve as a quantitative indicator of tumor presence and stage. A higher proportion of malignant epithelial cells might correlate with advanced disease or a higher tumor burden, potentially informing prognostic assessments.
• Therapeutic Targeting: Understanding the cellular composition of the tumor and its microenvironment is crucial for developing targeted therapies. The observation that epithelial cells are the primary proliferating component reinforces the importance of therapies directly targeting cancer cells (e.g., EGFR inhibitors for specific mutations, given 'EGFR_mutation' is in the obs metadata).
• Immunotherapy Context: The relative reduction of immune cells in the TME, particularly T cells, suggests a potential "cold" tumor phenotype in some cases, where immune cells are either excluded or inactivated. This highlights the ongoing challenge and potential for immunotherapies, which aim to reactivate or re-engage the immune system against cancer. Further investigation into the *functional state* of the remaining immune cells would be critical for predicting immunotherapy response. (For more on the tumor microenvironment and immunotherapy, see: PubMed search for "tumor microenvironment immunotherapy lung cancer")

7. T Cell Subset Population Dynamics in Lung Cancer Progression

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot visualizing the relative proportions of T cell subsets and related innate lymphoid cells (ILCs and NK cells) across different samples categorized into Normal, Tumor (early), and Tumor (advanced) conditions. The data is derived from single-cell RNA-seq of human lung tissue, focusing on the 'T cell' major population and its further refinement into 'subset' level categories. The primary goal is to identify shifts in the immune cell composition within the T cell compartment during lung cancer progression.

Visual Summary

The bar plot displays the percentage contribution of various T cell and innate lymphoid cell subsets for each individual sample, grouped by condition: Normal (9 samples), Tumor(adv) (3 samples), and Tumor(early) (8 samples).

• Normal Samples: The T cell compartment in normal lung tissue is predominantly composed of T cell (Cytotoxic), T cell (Naive), and T cell (Tfh) populations, which together constitute the majority. Other subsets, including various ILCs, NK cells, and T cell (Treg), are present in very low proportions.
• Tumor(early) Samples: A notable shift is observed, with a clear increase in the relative proportion of T cell (Treg) cells (represented by the dark blue segment) compared to normal samples. While T cell (Cytotoxic), T cell (Naive), and T cell (Tfh) remain major components, their relative contribution appears slightly reduced due to the expansion of Tregs. The "unassigned" category is minimal.
• Tumor(adv) Samples: This condition continues to show an elevated proportion of T cell (Treg) cells, consistent with the trend initiated in early-stage tumors. Furthermore, some advanced tumor samples (e.g., EBUS_06, EBUS_58) exhibit a noticeable increase in the "unassigned" population (darkest blue segment), suggesting either novel or unclassified cell states, or potentially increased cellular heterogeneity and perturbation in the advanced tumor microenvironment. ILCs and NK cells remain minor components across all conditions.

Biological Interpretation

The observed changes in T cell subset populations provide critical insights into the immune microenvironment of lung cancer.

1. Enrichment of Regulatory T cells (Tregs) in Tumor Conditions: A prominent finding is the consistent increase in T cell (Treg) populations in both early and advanced tumor samples compared to normal lung tissue. Tregs are potent immunosuppressive cells that play a crucial role in maintaining immune tolerance and preventing autoimmunity. Their enrichment within the tumor microenvironment is a well-established mechanism by which tumors evade anti-tumor immune responses, promoting tumor growth and progression PubMed search: regulatory T cells lung cancer immune evasion. This suggests that immunosuppression is an early event in lung cancer development and is sustained throughout progression.
2. Implication for Anti-tumor Immunity: The relative increase in Tregs, alongside the likely unchanged or relatively decreased proportions of potentially anti-tumor effector cells like T cell (Cytotoxic) cells, indicates a shift towards an immunosuppressive tumor microenvironment. This altered balance can hinder effective anti-tumor immune responses, allowing cancer cells to proliferate unchecked.
3. "Unassigned" Population in Advanced Tumors: The emergence of a more substantial "unassigned" population in some advanced tumor samples warrants further investigation. This could represent highly perturbed or novel T cell states induced by the advanced tumor microenvironment, or potentially cells with ambiguous transcriptomic profiles that do not clearly fit into predefined subsets. Characterizing these cells could reveal new insights into immune dysregulation in advanced disease.
4. Minor Role of ILCs and NK cells in T cell Compartment Shifts: While important immune components, the proportions of ILCs (ILC1, ILC2, ILC3, ILCreg, LTI) and NK cells remain consistently low and do not show significant proportional shifts within the T cell compartment across disease stages in this analysis. This suggests that changes in T cell subsets, particularly Tregs, are the primary drivers of immune compositional changes observed within this specific analysis of the broad T cell population.

Clinical or Translational Implications

The findings have several potential clinical and translational implications for lung cancer management:

1. Therapeutic Targeting of Tregs: The consistent and early enrichment of T cell (Treg) cells highlights them as attractive targets for immunotherapeutic interventions. Strategies aimed at depleting Tregs or inhibiting their suppressive function could help restore anti-tumor immunity and improve the efficacy of existing treatments, such as immune checkpoint inhibitors GeneCards: FOXP3, UniProt: FOXP3.
2. Biomarker Potential: The proportion of T cell (Treg) cells in the tumor microenvironment could serve as a prognostic biomarker for lung cancer progression or as a predictive marker for response to immunotherapies. Monitoring these cellular shifts could inform personalized treatment strategies.
3. Understanding Advanced Disease Heterogeneity: Further characterization of the "unassigned" cell population in advanced tumors could uncover novel immune cell states or therapeutic resistance mechanisms, potentially leading to the identification of new targets for advanced lung cancer.

8. Differential Abundance of T Cell Subsets and ILC2s in Lung Cancer Progression

[Analysis Visualization Results]...

Analysis Overview

This analysis presents box plots visualizing the proportional abundance of various T cell subsets and Group 2 innate lymphoid cells (ILC2s) across three conditions: "Tumor(early)", "Normal", and "Tumor(adv)" (advanced tumor). The goal is to identify and quantify statistically significant shifts in these immune cell populations during the progression of Lung Cancer. The tool plot_box_for_celltype_population_with_signif_difference was used, applying a p-value cutoff of 0.1 for statistical significance between conditions.

Visual Summary

The box plots illustrate the distribution of celltype proportions for eight distinct lymphoid populations (Tfh, Th22, NK, Th17, Th2, T_Naive, Treg, ILC2) across the "Tumor(early)", "Normal", and "Tumor(adv)" conditions. Statistically significant differences (p < 0.1) are highlighted with connecting lines and p-values.

• Tfh (T follicular helper) cells: Significantly elevated in "Tumor(early)" compared to "Normal" (p=2.66e-05). While not significantly different from "Normal" in "Tumor(adv)", Tfh cells show a marginally significant decrease from "Tumor(early)" to "Tumor(adv)" (p=0.0839).
• Th22 cells: Show a significant increase in "Tumor(early)" compared to "Normal" (p=3.62e-05). Proportions in "Tumor(adv)" are not significantly different from "Normal". However, a significant decrease is observed from "Tumor(early)" to "Tumor(adv)" (p=0.0382).
• NK (Natural Killer) cells: Markedly reduced in both "Tumor(early)" (p=6e-05) and "Tumor(adv)" (p=0.0124) compared to "Normal" tissue. There is no significant difference between early and advanced tumor stages.
• Th17 cells: Significantly increased in "Tumor(early)" when compared to "Normal" (p=0.000351). No significant differences were observed between "Tumor(adv)" and "Normal", or between "Tumor(early)" and "Tumor(adv)".
• Th2 cells: Display a significant increase in "Tumor(early)" relative to "Normal" (p=0.00431). In "Tumor(adv)", Th2 cells are marginally significantly lower than "Normal" (p=0.0828), and significantly reduced compared to "Tumor(early)" (p=0.00129).
• T_Naive cells: Significantly higher in both "Tumor(early)" (p=0.00136) and "Tumor(adv)" (p=0.0373) compared to "Normal" tissue. Their proportions remain comparable between early and advanced tumor stages.
• Treg (Regulatory T) cells: Significantly enriched in "Tumor(early)" samples relative to "Normal" (p=0.0015). No significant differences were detected when comparing "Tumor(adv)" with "Normal" or with "Tumor(early)".
• ILC2 (Group 2 innate lymphoid cells): While not significantly different between "Tumor(early)" and "Normal", ILC2 proportions are significantly lower in "Tumor(adv)" compared to "Normal" (p=0.00488). Furthermore, a significant decrease in ILC2s is observed from "Tumor(early)" to "Tumor(adv)" (p=0.0445).

Biological Interpretation

The observed shifts in T cell subsets and ILC2s reveal a dynamically changing immune microenvironment throughout lung cancer progression.

1. Early-Stage Immune Dysregulation: The "Tumor(early)" condition is characterized by a significant increase in several helper T cell subsets, including Tfh, Th22, Th17, Th2, and Treg cells, as well as T_Naive cells, compared to "Normal" tissue. This suggests an initial host immune response, possibly attempting to combat the tumor or contributing to a pro-inflammatory, pro-tumorigenic environment. The simultaneous significant decrease in NK cells in early tumor is critical, indicating an early immune evasion mechanism where the innate anti-tumor surveillance is suppressed or diminished. The rise in Tregs is a classic hallmark of immune tolerance induced by developing tumors, allowing them to evade destruction PubMed: Treg cells lung cancer immune suppression.
2. Progression to Advanced Disease and Immune Shifts: As the tumor progresses to "Tumor(adv)", distinct patterns emerge:
   • Persistent NK Cell Suppression: NK cell proportions remain significantly low in advanced tumors, reinforcing their role in immune evasion throughout disease progression PubMed: NK cell function lung cancer immune evasion.
   • Reduction in Helper T Cells: The proportions of Tfh, Th22, and Th2 cells significantly decrease from "Tumor(early)" to "Tumor(adv)", approaching or even falling below (Th2) "Normal" levels. This could indicate a shift from an initial, albeit dysregulated, immune activation towards immune exhaustion or a more immunosuppressive state in advanced cancer.
   • Sustained T_Naive Expansion: T_Naive cells remain significantly elevated in advanced tumors compared to normal, similar to early tumors. This might suggest a failure of effective T cell priming and activation, leading to an accumulation of uncommitted T cells in the tumor microenvironment.
   • ILC2 Decline in Advanced Disease: The significant decrease of ILC2s in advanced tumor stages compared to both normal and early tumor suggests a specific suppression of these innate lymphoid cells as the disease progresses. ILC2s are involved in type 2 immunity and tissue repair, and their reduction might reflect a changing inflammatory milieu or increased immunosuppression in the advanced tumor.

Clinical or Translational Implications

The differential abundance of these immune cell populations provides potential insights into lung cancer diagnosis, prognosis, and therapeutic strategies:

• Biomarkers: The proportion of NK cells, Treg cells, and several helper T cell subsets (Tfh, Th22, Th17, Th2, T_Naive) could serve as valuable biomarkers for differentiating early-stage lung cancer from normal tissue, and potentially for monitoring disease progression. For instance, low NK cell counts could indicate an early sign of immune evasion.

Immunotherapeutic Targets

• The consistent suppression of NK cells suggests that immunotherapies aimed at restoring or boosting NK cell function could be beneficial across all tumor stages.
• The significant increase in Treg cells in early tumors points to their critical role in early immune evasion. Targeting Tregs (e.g., via depletion or inhibition of their suppressive function) could be a promising strategy to enhance anti-tumor immunity, particularly in early-stage disease.
• The dynamic shifts in Th subpopulations (Tfh, Th22, Th17, Th2) between early and advanced stages imply that immune-modulating therapies may need to be tailored to the specific stage of the disease. For example, therapies designed to shift the immune balance away from pro-tumorigenic Th2 or Th17 responses might be considered.

• Prognostic Value: The specific immune cell profiles at different stages might correlate with patient prognosis, potentially guiding personalized treatment plans. The decline in protective or beneficial immune cell types (like ILC2s) or increase in immunosuppressive cells (like Tregs) could indicate a more aggressive disease course.

9. Macrophage Subpopulation Shifts Across Lung Cancer Stages

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot visualizing the relative proportions of various macrophage subsets (Macrophage (M1), Macrophage (M2A), Macrophage (M2B), Macrophage (M2C), Macrophage (M2D)) across individual samples, grouped by physiological conditions: Normal, Tumor (early), and Tumor (adv) in the lung tissue. Each bar represents 100% of the macrophage population within a given sample, illustrating the internal composition of macrophages. This helps to identify shifts in macrophage polarization that may be associated with lung cancer progression.

Visual Summary

The stacked bar plots display the relative abundances of five distinct macrophage subsets for each sample across the three conditions.

• Normal Condition: In normal lung samples (e.g., LUNG_N30, LUNG_N06), Macrophage (M1) and Macrophage (M2A) subsets are prominently represented, often constituting the majority of the macrophage population. Macrophage (M2B) and Macrophage (M2C) are present but in smaller proportions, while Macrophage (M2D) is consistently at very low levels. This suggests a relatively balanced macrophage phenotype in healthy lung tissue, with a significant representation of classically activated (M1-like) and alternatively activated (M2A-like) macrophages.
• Tumor (early) Condition: In early-stage tumor samples (e.g., LUNG_T30, LUNG_T09), there is an observable shift in macrophage composition. While Macrophage (M1) remains a substantial component, there appears to be an increase in the relative proportions of Macrophage (M2B) and Macrophage (M2C) compared to the normal condition. Macrophage (M2A) may show a slight decrease or stability in proportion.
• Tumor (adv) Condition: In advanced-stage tumor samples (e.g., BRONCHO_58, EBUS_49), this trend becomes more pronounced. Macrophage (M2B) and Macrophage (M2C) show a clear and often higher proportional increase compared to both Normal and Tumor (early) conditions. Macrophage (M1) still accounts for a significant portion, but its relative dominance might be attenuated due to the expansion of M2B and M2C populations. Macrophage (M2D) remains a minor subset across all conditions.

Overall, the visual data indicates a progressive shift in macrophage polarization from a more balanced M1/M2A profile in normal tissue towards an enrichment of M2B and M2C macrophage subsets as lung cancer progresses from early to advanced stages.

Biological Interpretation

Macrophages are highly plastic immune cells that can adopt diverse phenotypes, broadly categorized as M1 (classically activated) or M2 (alternatively activated), with various M2 subtypes (M2A, M2B, M2C, M2D) reflecting specific activation states and functions.

• M1 Macrophages are typically pro-inflammatory and anti-tumorigenic, producing cytokines like TNF-α and IL-1β, and exhibiting potent phagocytic and antigen-presenting capabilities. Their significant presence in normal tissue and sustained, albeit relatively diminished, presence in tumor conditions highlight their fundamental role in immune surveillance and host defense.
• M2 Macrophages, particularly M2B and M2C subtypes, are often associated with wound healing, tissue remodeling, angiogenesis, and immune suppression, all of which can contribute to tumor progression.
  • M2B macrophages can be activated by immune complexes and contribute to inflammation and immune regulation.
  • M2C macrophages are typically characterized by high expression of CD163 and CD206, contributing to immune suppression, tissue repair, and promoting tumor growth and metastasis by secreting factors like IL-10 and TGF-β PubMed Search: M2C macrophages cancer role.

The observed increase in Macrophage (M2B) and Macrophage (M2C) populations in both early and advanced lung tumor microenvironments strongly suggests a shift towards a pro-tumorigenic, immunosuppressive phenotype. This polarization of macrophages into tumor-associated macrophages (TAMs) is a well-established hallmark of cancer, where TAMs foster an environment conducive to tumor growth, invasion, and metastasis, and can inhibit anti-tumor immune responses GeneCards: Macrophage differentiation associated with tumor. Given that 'Lung Epithelial cell' is the resolved tumor-origin cell type, these M2-polarized macrophages likely interact with the tumor cells to facilitate disease progression.

The persistent presence of M1 macrophages even in advanced tumors indicates the complexity and heterogeneity of the tumor microenvironment, where both anti-tumor and pro-tumor forces may coexist. However, the proportional increase of M2-like subsets indicates a shift in the overall balance favoring tumor progression.

Clinical or Translational Implications

The progressive enrichment of M2B and M2C macrophage subsets in lung cancer suggests that targeting these pro-tumorigenic macrophages could be a viable therapeutic strategy.

• Immunosuppression and Therapy Resistance: The increased M2 populations contribute to the immunosuppressive microenvironment, potentially hindering the efficacy of immunotherapies such as checkpoint inhibitors. Strategies aimed at repolarizing M2 macrophages to M1-like phenotypes or depleting TAMs could enhance anti-tumor immunity PubMed Search: TAM repolarization cancer therapy.
• Biomarker Potential: The specific shifts in M2B and M2C proportions could serve as prognostic biomarkers for lung cancer progression or indicators of response to certain treatments. Monitoring these macrophage subsets might provide insights into disease aggressiveness and guide treatment decisions.
• Targeted Therapies: Developing therapies that specifically inhibit the recruitment, survival, or pro-tumor functions of M2B and M2C macrophages could offer novel avenues for lung cancer treatment. This could involve blocking chemokine receptors involved in macrophage recruitment (e.g., CCR2, CXCR4) or pathways that promote M2 polarization (e.g., STAT3, IRF4) UniProt: STAT3 function in macrophages.

10. Macrophage Subset Population Shifts Across Lung Cancer Progression

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional changes of specific macrophage subsets (Mac (M2B), Mac (M2A), and Mac (M2C)) across different lung conditions: "Normal," "Tumor(early)," and "Tumor(adv)" (advanced tumor). The goal is to identify statistically significant shifts in these immune cell populations during lung cancer development and progression, which can provide insights into their potential roles in the tumor microenvironment. Statistical significance was determined using a p-value cutoff of 0.1.

Visual Summary

The box plots illustrate the celltype proportion for three macrophage subsets across the specified conditions, with black dots representing individual sample data points.

Mac (M2B) Proportions:

• Mac (M2B) cell proportions show a statistically significant increase from Normal to Tumor(early) (p=0.0462).
• There is a highly significant and substantial increase in Mac (M2B) proportions in advanced tumors compared to normal tissue (p=1.34e-05).
• Furthermore, Mac (M2B) proportions are significantly higher in Tumor(adv) compared to Tumor(early) (p=0.000245).
• Overall, Mac (M2B) cell proportions exhibit a clear and significant upward trend as lung cancer progresses from normal to early-stage and further to advanced-stage disease.

Mac (M2A) Proportions:

• Mac (M2A) cell proportions are significantly lower in Tumor(early) compared to Normal tissue (p=0.0242).
• This decrease becomes even more pronounced and highly significant in Tumor(adv) relative to Normal tissue (p=0.00248).
• A significant reduction in Mac (M2A) proportions is also observed from Tumor(early) to Tumor(adv) (p=0.0329).
• In summary, Mac (M2A) cell proportions demonstrate a consistent and significant decline with lung cancer progression.

Mac (M2C) Proportions:

• No statistically significant difference in Mac (M2C) proportions is observed between Tumor(early) and Normal conditions (p=0.911).
• However, Mac (M2C) proportions are significantly lower in Tumor(adv) compared to Normal tissue (p=0.0941).
• The difference between Tumor(adv) and Tumor(early) did not reach statistical significance at the p < 0.1 cutoff (p=0.1).
• Overall, Mac (M2C) shows a significant decrease only in the advanced tumor stage compared to normal tissue, without a clear progressive trend from early tumor stages.

Biological Interpretation

Macrophages are critical components of the tumor microenvironment (TME) and are often broadly classified into M1 (pro-inflammatory, anti-tumor) and M2 (anti-inflammatory, pro-tumor) phenotypes, though their polarization is more complex and exists on a spectrum. The observed shifts in macrophage subsets provide crucial insights into their evolving roles during lung cancer progression.

The most striking finding is the significant and progressive increase in Mac (M2B) proportions from normal to early tumor and further to advanced tumor stages. M2 macrophages, including subtypes like M2B, are generally associated with tumor progression, angiogenesis, immune suppression, and tissue remodeling, all of which support cancer growth and metastasis [1]. The rising proportion of Mac (M2B) as the tumor advances suggests their increasing recruitment and/or polarization within the TME, contributing to an immunosuppressive and pro-tumorigenic milieu in lung cancer.

Conversely, the significant decrease in Mac (M2A) proportions across tumor stages (Tumor(early) < Normal, Tumor(adv) < Normal, and Tumor(adv) < Tumor(early)) indicates a diminishing presence of this specific M2 subset as the disease progresses. While M2 macrophages are broadly pro-tumorigenic, different M2 subsets can have distinct functional roles. A decrease in M2A might reflect a shift in the specific types of pro-tumorigenic macrophages or a relative dominance of other subsets like M2B. Some studies suggest M2A can be associated with wound healing and fibrosis, and its reduction might imply a shift away from these specific activities or a selection for other M2 subtypes more directly involved in advanced tumor pathology.

For Mac (M2C), the significant decrease only in advanced tumors compared to normal tissue (p=0.0941) suggests a more specific alteration at later stages of the disease. M2C macrophages are known for their immunosuppressive functions, promoting immune tolerance, tissue repair, and phagocytosis of apoptotic cells [2]. Their reduction in advanced tumors could imply a complex rearrangement of the TME, where other immunosuppressive mechanisms might become dominant, or their specific roles are diminished, perhaps replaced by the more rapidly expanding M2B population.

The overall picture in lung cancer progression appears to be characterized by an accumulation of Mac (M2B) cells, which are strongly implicated in tumor promotion, while Mac (M2A) and to some extent Mac (M2C) populations decline. This suggests a dynamic remodeling of the macrophage compartment within the TME, favoring specific pro-tumorigenic M2 subsets as lung cancer advances.

Clinical or Translational Implications

The distinct and statistically significant changes in macrophage subset proportions across lung cancer stages have several potential clinical and translational implications:

1. Biomarkers for Disease Progression: The increasing proportion of Mac (M2B) and decreasing proportion of Mac (M2A) could serve as potential biomarkers for lung cancer progression. Monitoring these ratios in patient samples might offer prognostic value, indicating the stage or aggressiveness of the tumor.
2. Therapeutic Targets: Given the pro-tumorigenic role of M2B macrophages, targeting these cells or their polarization pathways could be a viable therapeutic strategy in lung cancer [3]. Interventions aimed at depleting M2B cells, reprogramming them towards an anti-tumor M1 phenotype, or inhibiting their recruitment could potentially slow tumor growth and enhance anti-tumor immunity.
3. Immunotherapy Response Prediction: The specific balance of macrophage subsets in the TME is known to influence the response to various immunotherapies. Understanding these shifts could help predict which patients might benefit most from certain treatments or guide the development of combination therapies that modulate macrophage polarization alongside other immunomodulatory agents.
4. Novel Drug Development: The differential changes in M2A, M2B, and M2C populations highlight the complexity of macrophage phenotypes in cancer. Developing drugs that specifically target the pathways driving the accumulation of pro-tumorigenic M2B macrophages, or prevent the decrease of potentially beneficial macrophage subtypes, could offer more precise and effective cancer treatments.

References

1. M2 Macrophages and Tumor Progression:

PubMed Search: "M2 macrophages tumor progression"

2. M2C Macrophage Functions:

PubMed Search: "M2c macrophages immune suppression"

3. Targeting Macrophages in Cancer Therapy:

PubMed Search: "targeting M2 macrophages cancer therapy"

11. Ploidy Analysis of Tumor-Origin Lung Epithelial Cells

[Analysis Visualization Results]...

Analysis Overview

This analysis examines the ploidy status (Diploid, Aneuploid, Unclear) of Lung Epithelial cells, identified as the tumor-origin cell type, across samples from three conditions: Normal, Tumor (advanced), and Tumor (early). The objective is to understand how chromosomal instability, reflected by aneuploidy, correlates with disease state in lung cancer. The results are presented as stacked bar plots, where each bar represents a single sample, showing the proportional distribution of ploidy populations within its Lung Epithelial cells.

Visual Summary

The stacked bar plots effectively demonstrate distinct ploidy patterns in Lung Epithelial cells across the different conditions and individual samples.

• Normal Condition: In all normal lung samples (LUNG_N01, LUNG_N34, LUNG_N31, LUNG_N30, LUNG_N28, LUNG_N19, LUNG_N20, LUNG_N18, LUNG_N09, LUNG_N06, LUNG_N08), Lung Epithelial cells are uniformly 100% Diploid (orange bars). This establishes a clear baseline of genomic stability in healthy tissue.
• Tumor (advanced) Condition: Samples from advanced tumors (EBUS_06, EBUS_28, BRONCHO_58, EBUS_49) display a predominant aneuploid (dark red) population among Lung Epithelial cells. Specifically, EBUS_06 and EBUS_28 show nearly 100% aneuploidy, BRONCHO_58 has approximately 90% aneuploid cells, and EBUS_49 contains about 62% aneuploid cells. This indicates widespread genomic instability in advanced disease.
• Tumor (early) Condition: The early tumor samples present a more heterogeneous ploidy profile. A significant portion of these samples (LUNG_T18, LUNG_T34, LUNG_T28, LUNG_T20, LUNG_T08, LUNG_T19, LUNG_T06, LUNG_T31) exhibit a substantial percentage of aneuploid cells, ranging from roughly 55% to 98%. However, other early tumor samples (LUNG_T30, LUNG_T25, LUNG_T09) show a lower, but still present, proportion of aneuploid cells (approximately 27%, 25%, and 13% respectively), with a larger fraction of diploid cells. The "Unclear" ploidy population (light green) is negligible across all samples and conditions.

Biological Interpretation

The observed ploidy changes in Lung Epithelial cells provide strong biological insights into lung cancer development and progression, consistent with their identification as the tumor-origin cell type.

• Genomic Integrity in Health: The exclusive diploidy in normal Lung Epithelial cells underscores the stringent maintenance of genomic stability in healthy tissues, which is essential for normal cellular function and preventing malignant transformation.
• Aneuploidy as a Driver of Oncogenesis: The dramatic shift to aneuploidy in tumor-derived Lung Epithelial cells is a hallmark of cancer. Aneuploidy, characterized by an abnormal chromosome number, is a major contributor to genomic instability and a driver of tumor evolution by altering gene dosage, affecting cell cycle regulation, and promoting cellular heterogeneity and adaptation within the tumor microenvironment.
• Correlation with Tumor Progression: The increasing trend of aneuploidy from normal, through early-stage, to advanced-stage tumors suggests that genomic instability accumulates as the disease progresses. While early tumors show variability, with some retaining a significant diploid component, advanced tumors almost universally exhibit high levels of aneuploidy. This indicates that sustained and widespread aneuploidy is likely critical for the establishment and aggressive growth of advanced lung cancer.
• Role of Tumor-Origin Cells: Since Lung Epithelial cells are the resolved tumor-origin cell type, the observed aneuploidy directly reflects the genetic alterations within the cells that initiated and propagate the cancer, confirming their central role in the pathogenesis of lung cancer.

Clinical or Translational Implications

• Biomarker for Diagnosis and Staging: The prevalence and degree of aneuploidy in Lung Epithelial cells could serve as a valuable diagnostic and prognostic biomarker for lung cancer. High levels of aneuploidy clearly distinguish tumor tissue from normal tissue. Furthermore, the varying levels of aneuploidy in early-stage tumors might help in sub-classifying tumors based on their genetic instability, potentially aiding in identifying more aggressive forms of early disease or predicting therapeutic response.
• Monitoring Disease Progression: Monitoring ploidy changes in Lung Epithelial cells over time, potentially through liquid biopsies or sequential tissue sampling, could offer insights into tumor evolution, detect disease progression, or assess resistance to therapy. An increasing aneuploid fraction could signal disease advancement.
• Therapeutic Strategies: Understanding the mechanisms that lead to and sustain aneuploidy in Lung Epithelial cells could uncover novel therapeutic targets. Strategies aimed at inducing mitotic catastrophe in aneuploid cells, restoring chromosomal stability, or targeting specific vulnerabilities arising from aneuploidy are active areas of cancer research.
  • For further reading on the role of aneuploidy in cancer biology: PubMed search for "aneuploidy cancer review"

12. Cell-Cell Interaction Patterns in Lung Cancer Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns involving key cell types within the lung tissue microenvironment across normal, early-stage tumor, and advanced-stage tumor conditions. The primary focus is on interactions concerning the identified tumor-origin cells (Lung Epithelial cells, specifically aneuploid), alongside immune cells (T cells, B cells, Macrophages, Dendritic cells) and stromal components (Fibroblasts, Endothelial cells). The goal is to identify significant ligand-receptor mediated communications that characterize tumor development and progression, highlighting potential therapeutic targets.

Visual Summary

The provided dot plots illustrate the strength (color intensity, log2(mean expression)) and statistical significance (dot size, -log10(p-value)) of various cell-cell interactions. Each plot represents a distinct condition: Normal, Tumor (early), and Tumor (adv).

• Overall Interaction Landscape: A diverse set of ligand-receptor pairs mediate interactions across all conditions. Integrin complexes, adhesion molecules (e.g., ICAM1), and growth factor/cytokine signaling (e.g., VEGFA, TNFSF families) are prominent.

Condition-Specific Patterns:

• Normal Condition: Displays a baseline of interactions, primarily involving 'Diploid Lung Epi' cells. Homotypic interactions (e.g., 'Diploid Lung Epi/Diploid Lung Epi', 'Mac/Mac', 'T CD8+/T CD8+') and interactions important for tissue homeostasis are observed.
• Tumor (early) and Tumor (adv) Conditions: A marked shift is observed with the emergence of interactions involving 'Aneuploid Lung Epi' cells, reflecting the tumor's presence. There is an overall increase in the number and strength of specific interactions, particularly between tumor cells and the surrounding stromal and immune cells.
• Progression from Early to Advanced Tumor: While many key tumor-associated interactions are already established in the early tumor stage, some pathways appear to intensify or broaden in the advanced stage, indicating a more complex and aggressive tumor microenvironment.

Biological Interpretation

1. Tumor-Origin Cell Interactions (Aneuploid Lung Epithelial Cells)

• Homotypic Interactions: 'Aneuploid Lung Epi/Aneuploid Lung Epi' interactions are observed in both tumor conditions via adhesion molecules such as CDH1_integrin_aE_b7_complex, LAMC1_integrin_a2b1_complex, and ICAM1_integrin_aMb2_complex. These interactions likely contribute to tumor cell cohesion and the establishment of a solid tumor mass, reflecting altered epithelial cell-cell adhesion in cancer.

Tumor-Stromal Crosstalk:

• Aneuploid Lung Epi - Fibroblast: A significant upregulation of integrin-mediated interactions, including FN1_integrin_a5b1_complex, FN1_integrin_aVb1_complex, SPP1_integrin_a3b1_complex, and COL1A1_integrin_aVb1_complex, is evident in both tumor conditions compared to normal. These interactions suggest active extracellular matrix (ECM) remodeling and strong reciprocal support between tumor cells and tumor-associated fibroblasts (TAFs), promoting tumor growth and invasion.
• Aneuploid Lung Epi - Endothelial Cell: The VEGFA_VEGFR1, VEGFA_VEGFR2, and VEGFA_NRP1 axes show robust activity from 'Aneuploid Lung Epi' to 'Endothelial cell' in both early and advanced tumor stages. This strongly indicates tumor-driven angiogenesis, a critical hallmark of cancer, where tumor cells stimulate the formation of new blood vessels to support their growth. The ICAM1_integrin_aMb2_complex also mediates this crosstalk.

Tumor-Immune Cell Interactions:

• Aneuploid Lung Epi - T cells (CD8+/CD4+): ICAM1_integrin_aMb2_complex is a prominent interaction, potentially influencing T cell trafficking or immune synapse formation. TNFSF18_TNFRSF18 (GITRL-GITR) interactions are also noted, which can modulate T cell activation and function, potentially contributing to immune evasion or exhaustion within the tumor microenvironment.
• Aneuploid Lung Epi - Macrophage: APOE_TREM2 is consistently observed, suggesting a role for macrophages (possibly tumor-associated macrophages, TAMs) in interacting with tumor cells, potentially influencing tumor immunity or promoting tumor growth.
• Aneuploid Lung Epi - B cell: Interactions via CD47_SIRPA and CD320_CD320 are present. CD47-SIRPA signaling is known to provide a "don't eat me" signal, allowing tumor cells to evade phagocytosis by macrophages.

2. Macrophage-Specific Interactions

• Mac/Mac Homotypic Interactions: APOE_TREM2 is a highly significant and strong interaction among macrophages across all conditions, implying critical self-regulation or coordinated immune responses.
• Mac/T cell Interactions: ICAM1_integrin_aMb2_complex and SPP1_integrin_aMb2_complex mediate interactions between macrophages and T cells, crucial for antigen presentation and immune cell recruitment.

3. T Cell and Other Immune Cell Interactions

• T cell Homotypic/Heterotypic: CD99_CD99 is notable in 'T CD8+/T CD8+' and 'T CD4+/T CD4+' interactions in the normal condition, indicating baseline lymphocyte communication.
• NK/Mac: SPP1_integrin_aMb2_complex appears in 'NK/Mac' interactions, potentially influencing NK cell activity or macrophage-NK cell crosstalk.

Clinical or Translational Implications

The differential cell-cell interaction patterns identified in this analysis offer several promising avenues for therapeutic targeting and deeper investigation in Lung Cancer:

• Anti-angiogenic Therapy: The robust and persistent activation of the VEGFA_VEGFR axis between Aneuploid Lung Epithelial cells and Endothelial cells in both early and advanced tumor stages is a strong indicator of its critical role in lung tumor angiogenesis. This pathway is a well-established therapeutic target in various cancers, and its prominence here further supports the use of anti-VEGF/VEGFR agents (e.g., bevacizumab or VEGFR tyrosine kinase inhibitors) to inhibit tumor blood supply in lung cancer patients PubMed Search: VEGF inhibitors lung cancer.
• Targeting Tumor-Associated Fibroblasts (TAFs): The heightened integrin-mediated interactions between 'Aneuploid Lung Epi' and 'Fibroblasts' (e.g., via FN1, SPP1, COL1A1) underscore the pivotal role of TAFs in tumor progression. Disrupting these interactions could impede ECM remodeling, reduce stromal support for tumor growth, and enhance drug delivery. Targeting specific integrins or ECM components involved in these pathways could represent a novel therapeutic strategy GeneCards: ITGA5.

Immunomodulation:

• The TNFSF18_TNFRSF18 (GITRL-GITR) axis between tumor cells and T cells presents an opportunity for immune modulation. GITR agonists are explored in immunotherapy to enhance anti-tumor T cell responses PubMed Search: GITR agonists cancer immunotherapy.
• The consistent presence of APOE_TREM2 interactions involving macrophages and tumor cells warrants further investigation into its role in TAM polarization and function. Modulating TREM2 signaling could potentially reprogram TAMs from pro-tumorigenic to anti-tumorigenic states.
• The CD47_SIRPA "don't eat me" signal from tumor cells to B cells (and potentially other phagocytes) is a known immune evasion mechanism. CD47-blocking antibodies are currently in clinical trials for various cancers, aiming to enable phagocytosis of tumor cells UniProt: P16422 (CD47).

• Adhesion Molecule Targeting: The pervasive involvement of ICAM1_integrin_aMb2_complex (LFA-1/ICAM-1) in tumor-immune and tumor-endothelial cell interactions suggests its importance in immune cell trafficking and potential metastasis. Interfering with this axis could affect immune cell infiltration and tumor spread.

13. Condition-Specific Cell-Cell Interaction Patterns in Lung Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interactions (CCIs) involving Lung Epithelial cells (identified as the tumor-origin cell type) and major immune and stromal cells across Normal, Tumor(early), and Tumor(adv) conditions in lung tissue samples. The goal is to identify significantly different interaction patterns that may underpin disease progression and reveal potential therapeutic targets. The CellPhoneDB tool was used to predict ligand-receptor interactions, and the results are visualized as a dot plot, showing interaction strength (color intensity) and significance (dot size) for each sample and condition.

Visual Summary

The dot plot visualizes a comprehensive landscape of cell-cell interactions, faceted by condition: Normal, Tumor(adv), and Tumor(early).

• Overall Pattern: The plot reveals distinct patterns of cell-cell communication across conditions. In general, a high number of significant interactions are observed in the Normal samples (left panel). Many of these interactions, particularly those involving Lung.Epi (Dip) (Diploid Lung Epithelial cells) and Macrophages, appear to be attenuated or altered in tumor conditions. Conversely, the tumor conditions (Tumor(adv) and Tumor(early) panels) show the emergence or enhancement of a new set of interactions, predominantly involving Lung.Epi (Aneupl) (Aneuploid Lung Epithelial cells, likely representing tumor cells), Macrophages, Fibroblasts, Endothelial cells, and various T cell subsets.
• Normal Condition Highlights: A strong cluster of interactions is evident in Normal samples, often involving Mac | Mac, Mac | NK, Mac | T CD8+, and Lung.Epi (Dip) with immune cells. Examples include ICAM1_integrin_aLb2_complex -- Lung.Epi (Dip) | Mac and CD55_ADGRE5 -- Lung.Epi (Dip) | Mac, which show high activity in normal tissue but are less prominent or altered in tumor states.
• Tumor Condition Highlights (Tumor(adv) and Tumor(early)): Both tumor conditions exhibit a shift in the CCI landscape.
  • Emergence of Aneuploid Lung Epithelial Cell Interactions: A significant number of highly active interactions involve Lung.Epi (Aneupl) cells. These interactions are often strong (dark red, large dots) and frequently involve immune cells (T CD8+, T CD4+, B cell, Macrophage, NK) and stromal cells (Fibroblast, Endothelial cell). This strongly suggests that tumor cells are actively communicating with their microenvironment.
  • Immune Modulation: Interactions such as ProstaglandinE2_byPTGES3_PTGER2 -- Lung.Epi (Aneupl) | T CD8+ and atRetinoicAcid_byALDH1A1_RAReceptor_RXRB -- Lung.Epi (Aneupl) | B cell are notably strong in tumor samples, pointing towards active immune suppressive mechanisms mediated by tumor cells.
  • Stromal Remodeling and Angiogenesis: Interactions involving Fibroblasts and Endothelial cells, often with Lung.Epi (Aneupl) or other stromal components, become highly prominent in both early and advanced tumor stages. For instance, VEGFB_NRP1 -- Lung.Epi (Aneupl) | Endo and various COL1A1_integrin_a1b1_complex -- Lung.Epi (Aneupl) | Fib interactions are highly active in tumor samples. This indicates extensive extracellular matrix remodeling and angiogenesis supporting tumor growth.
  • Autocrine/Paracrine Tumor Signaling: An interaction like TGFB1_TGFbeta_receptor1 -- Lung.Epi (Aneupl) | Lung.Epi (Aneupl) suggests autocrine/paracrine signaling among tumor cells.
• Differences between Early and Advanced Tumor: While there's substantial overlap, some interactions might show subtle differences in strength or prevalence between Tumor(early) and Tumor(adv), potentially reflecting progression-related changes in the tumor microenvironment.

Biological Interpretation

The differential cell-cell interaction patterns highlight key biological processes disrupted or activated in lung cancer, providing insights into tumor-microenvironment co-evolution.

1. Tumor Cell-Mediated Immunosuppression:
   • Prostaglandin E2 (PGE2) Signaling: The strong interaction of ProstaglandinE2_byPTGES3_PTGER2 from Lung.Epi (Aneupl) to T CD8+ cells (and other immune cells via PTGER4 on B cells and T CD4+ cells) is a critical finding. PGE2, often produced by tumor cells (indicated by PTGES3), is a potent immunosuppressant in the tumor microenvironment. It can inhibit the activation and proliferation of CD8+ T cells, promote the differentiation of regulatory T cells (Tregs), and influence myeloid-derived suppressor cells (MDSCs), ultimately contributing to immune evasion by the tumor. PubMed search for "PGE2 lung cancer immune suppression"
   • Retinoic Acid Signaling: The observed atRetinoicAcid_byALDH1A1_RAReceptor_RXRB -- Lung.Epi (Aneupl) | B cell and atRetinoicAcid_byALDH1A1_RAReceptor_RXRA -- Lung.Epi (Aneupl) | Mac interactions suggest that aneuploid lung epithelial cells (tumor cells) expressing ALDH1A1 might be producing retinoic acid (RA). RA can profoundly influence immune cell differentiation and function, often promoting tolerogenic immune responses by inducing Tregs or impairing effector T cell function, thus contributing to an immunosuppressive environment. PubMed search for "retinoic acid lung cancer immune microenvironment ALDH1A1"
2. Angiogenesis and Extracellular Matrix (ECM) Remodeling:
   • VEGFB-NRP1 Axis: The prominent VEGFB_NRP1 -- Lung.Epi (Aneupl) | Endo interaction indicates active communication between tumor cells and endothelial cells. While VEGFA is the primary driver of pathological angiogenesis, VEGFB, often with Neuropilin-1 (NRP1), also contributes to vascular development and tumor growth. NRP1, expressed on endothelial cells, acts as a co-receptor for various growth factors, modulating angiogenesis and also influencing immune cell function, including Treg activity. GeneCards for NRP1
   • Collagen-Integrin Interactions: Numerous COL1A1_integrin_a1b1_complex -- Lung.Epi (Aneupl) | Fib and other collagen-integrin interactions highlight the extensive remodeling of the extracellular matrix (ECM) in the tumor microenvironment. Cancer-associated fibroblasts (CAFs) are key players in producing ECM components like Collagen I (COL1A1). Integrins mediate cell-ECM adhesion and signal transduction, which are crucial for tumor cell proliferation, survival, migration, and invasion. This intricate interplay creates a pro-tumorigenic niche. GeneCards for COL1A1
3. Autocrine/Paracrine Tumor Growth Signaling:
   • TGFB1 Signaling: The TGFB1_TGFbeta_receptor1 -- Lung.Epi (Aneupl) | Lung.Epi (Aneupl) interaction points to autocrine or paracrine TGF-beta signaling within the tumor cell population. Transforming Growth Factor-beta (TGF-beta) is a pleiotropic cytokine that can promote tumor cell growth, epithelial-mesenchymal transition (EMT), immune suppression, and metastasis in advanced cancers. This self-sustaining signaling loop is a hallmark of many solid tumors. PubMed search for "TGF-beta lung cancer progression"
4. Altered Adhesion and Immune Evasion:
   • ICAM1-Integrin: The reduced ICAM1_integrin_aLb2_complex -- Lung.Epi (Dip) | Mac in tumor conditions compared to normal, alongside the emergence of ICAM1_integrin_aLb2_complex -- Lung.Epi (Aneupl) | T CD8+ in tumor, suggests a shift in cell adhesion dynamics. Altered ICAM1 expression on tumor cells can impact immune cell recognition and cytotoxic activity, contributing to immune evasion.

Clinical or Translational Implications

The identified condition-specific CCIs represent promising avenues for therapeutic intervention in lung cancer.

Targeting Immunosuppressive Pathways:

• PGE2 Pathway: Given the strong PGE2-PTGER interactions, inhibiting PGE2 synthesis (e.g., via COX-2 inhibitors like celecoxib, though with cardiovascular concerns) or antagonizing its receptors (e.g., EP2/EP4 receptor antagonists) could reverse immune suppression, enhance anti-tumor immunity, and improve responses to immunotherapies. PubMed search for "PGE2 inhibitors cancer immunotherapy"
• Retinoic Acid Pathway: Modulating the retinoic acid signaling axis, perhaps by inhibiting ALDH1A1 activity or targeting specific RAR/RXR isoforms on immune cells, could alleviate immune suppression. Retinoids (e.g., ATRA) are used in some cancers, but their role in lung cancer TME modulation requires careful context-dependent investigation.

Inhibiting Angiogenesis and ECM Remodeling:

• NRP1 Inhibition: Targeting NRP1, which is involved in VEGFB-NRP1 interactions and potentially other pro-angiogenic or immunosuppressive pathways, could disrupt tumor angiogenesis and enhance anti-tumor immunity. Specific NRP1 inhibitors are under investigation. PubMed search for "NRP1 inhibitor cancer therapy"
• Integrin Blockade: Inhibiting specific integrins, such as those forming complexes with COL1A1, could disrupt tumor cell adhesion, migration, invasion, and metastasis. Integrin inhibitors (e.g., cilengitide, though for alphaVbeta3) have been explored in cancer, and targeting the relevant alpha1beta1 integrin in lung cancer could be beneficial.

Blocking Autocrine/Paracrine Tumor Growth:

• TGF-beta Inhibition: The prominent autocrine TGFB1-TGFbeta_receptor1 signaling among aneuploid lung epithelial cells highlights TGF-beta as a key driver of tumor progression. TGF-beta inhibitors (e.g., galunisertib, fresolimumab) are being developed to block its pro-tumorigenic and immunosuppressive effects. PubMed search for "TGF-beta inhibitors lung cancer"

These interactions provide a molecular blueprint of the lung cancer microenvironment, offering testable hypotheses for combination therapies and precision medicine approaches aimed at disrupting tumor-supporting communication networks.

14. Condition-Specific Cell-Cell Interaction Patterns in Lung Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interaction (CCI) patterns involving Lung Epithelial cells (identified as tumor-origin), major immune cells, and stromal cells in lung tissue from Normal, Tumor (early), and Tumor (advanced) conditions. The focus is on interactions mediated by genes associated with immune checkpoints and cell cycle pathways. The results are visualized as a dot plot, where the size of the dot represents the significance (-log10(p-value)) and the color intensity represents the scaled interaction strength. The plot displays interactions that differ significantly between conditions, highlighting key communication pathways within the tumor microenvironment (TME).

Visual Summary

The dot plot effectively illustrates distinct patterns of cell-cell communication across Normal, Tumor (advanced), and Tumor (early) conditions.

1. Condition-Specific Clustering: Samples largely cluster by condition, with Normal samples exhibiting a unique set of strong interactions (top-left blue box), while Tumor (advanced) and Tumor (early) samples share a highly overlapping and distinct pattern of interactions (middle-right blue box). This suggests a fundamental shift in cell communication in the cancerous state, which is largely established by the early tumor stage.
2. Dominance of Aneuploid Lung Epithelial Cells in Tumor: Interactions prominent in tumor conditions (Tumor(adv) and Tumor(early)) overwhelmingly involve Lung.Epi (Aneuploid) cells, confirming their central role as the tumor-origin cell type and highlighting the involvement of malignant cells in these dysregulated interactions. In contrast, normal-specific interactions primarily involve Lung.Epi (Dip) (Diploid Lung Epithelial cells).
3. Key Pathways and Cell Types in Tumor:
   • EGFR Signaling: Interactions involving EGFR ligands (AREG, EREG, HBEGF, BTC, TGFA) and the EGFR receptor are highly prevalent and strong in both tumor conditions. These involve Lung.Epi (Aneuploid) interacting with itself (autocrine/paracrine stimulation) as well as with Macrophages (Mac) and Fibroblasts (Fib).
   • TGF-beta Signaling: TGFB1 and TGFB3 interactions with TGF-beta receptors (TGFBeta_receptor1, TGFBeta_receptor2, TGFBR3) and integrin complexes (integrin_aVb6_complex) are also highly active in tumor samples. These primarily involve Lung.Epi (Aneuploid) interacting with Macrophages, Fibroblasts, and various immune cells (T CD8+, B cell, ILC).
   • Interferon (IFN) Signaling: While some IFN-gamma (IFNG_Type_II_IFNR) interactions are present in normal samples (e.g., with NK cells and T CD8+), they persist and often strengthen in tumor conditions with Lung.Epi (Aneuploid). Notably, CD93_IFNGR1 interactions involving Endothelial cells (Endo) and Macrophages with Lung.Epi (Aneuploid) also become prominent in tumor.
   • Immune Checkpoint/Co-stimulatory Interactions: Interactions like CD80 CD28 -- Lung.Epi (Aneuploid) | B cell and LCK_CD8_receptor -- Lung.Epi (Aneuploid) | ILC emerge as significant in tumor samples, suggesting altered immune regulation.
4. No Major Differences Between Early and Advanced Tumor: For the selected top significant interactions, there doesn't appear to be a drastic qualitative or quantitative difference in the interaction patterns between Tumor (early) and Tumor (advanced) samples. The core dysregulated communication network seems to be largely established early in tumor progression.

Biological Interpretation

The observed CCI patterns reveal critical shifts in the lung tumor microenvironment, emphasizing the complex interplay between malignant epithelial cells, immune cells, and stromal cells.

EGFR Signaling in Tumor Progression

• Mechanism: Epidermal Growth Factor Receptor (EGFR) is a receptor tyrosine kinase that, upon ligand binding, activates downstream pathways (e.g., MAPK/ERK, PI3K/AKT) crucial for cell proliferation, survival, and migration. Dysregulation of EGFR signaling is a major driver in many cancers, including lung cancer PubMed search: EGFR signaling lung cancer.
• Normal vs. Tumor Shift: In normal tissue, interactions like HBEGF_EGFR -- Mac | Lung.Epi (Dip) might contribute to tissue repair and homeostasis. In contrast, tumor conditions show robust and diverse EGFR-mediated interactions involving Lung.Epi (Aneuploid).

Key Tumor Interactions:

• EREG_EGFR -- Lung.Epi (Aneuploid) | Lung.Epi (Aneuploid): This strong interaction suggests an autocrine or paracrine loop where aneuploid tumor cells produce Epiregulin (EREG) to stimulate their own growth and survival via EGFR, a classic mechanism of oncogene addiction in cancer. GeneCards: EREG
• AREG_EGFR -- Lung.Epi (Aneuploid) | Mac: Amphiregulin (AREG) from tumor cells can activate EGFR on macrophages, promoting their pro-tumorigenic polarization (e.g., M2 phenotype). These macrophages then contribute to tumor growth, angiogenesis, and immune suppression, creating a supportive TME.
• HBEGF_EGFR -- Lung.Epi (Aneuploid) | Fib: Heparin-binding EGF-like growth factor (HBEGF) from tumor cells can activate EGFR on fibroblasts, leading to their differentiation into cancer-associated fibroblasts (CAFs). CAFs remodel the extracellular matrix, promote tumor invasion, and foster immunosuppression.

TGF-beta Pathway Remodeling the Tumor Microenvironment

• Mechanism: Transforming Growth Factor-beta (TGF-beta) is a pleiotropic cytokine with context-dependent roles in cancer. While initially tumor-suppressive, in later stages, it promotes tumor growth, invasion, metastasis, angiogenesis, and immune evasion PubMed search: TGF-beta lung cancer. Its signaling through serine/threonine kinase receptors activates SMAD-dependent and SMAD-independent pathways.
• Normal vs. Tumor Shift: Normal samples show TGFB1_integrin_aVb6_complex -- Mac | Lung.Epi (Dip), potentially involved in normal tissue repair or immune regulation. In tumor, the interactions shift to involve aneuploid epithelial cells.

Key Tumor Interactions:

• TGFB1_TGFbeta_receptor2 -- Mac | Lung.Epi (Aneuploid): Macrophage-derived TGFB1 can activate TGF-beta receptors on aneuploid lung epithelial cells, driving processes like epithelial-mesenchymal transition (EMT), which enhances tumor cell invasiveness and resistance to therapy. GeneCards: TGFB1
• TGFB3_TGFBR3 -- Lung.Epi (Aneuploid) | Fib: Tumor-derived TGFB3 interacting with TGFBR3 on fibroblasts can further activate CAFs, leading to desmoplasia and a stiffened ECM that facilitates tumor progression and hinders drug delivery.
• Various TGFB1_integrin_aVb6_complex interactions with Lung.Epi (Aneuploid) and immune/stromal cells indicate broad activation of latent TGF-beta, further shaping the immunosuppressive and pro-fibrotic TME.

Interferon Signaling and Immune Context

• Mechanism: Interferon-gamma (IFN-gamma) is a crucial cytokine produced by immune cells (e.g., NK cells, T cells) that plays a central role in anti-tumor immunity. It signals through IFN-gamma receptors (IFNGR) to activate STAT1 and induce expression of MHC molecules and immunoproteasome components GeneCards: IFNGR1. However, tumors can develop mechanisms of adaptive resistance to IFN-gamma, for instance by upregulating PD-L1 expression.

Key Tumor Interactions:

• IFNG_Type_II_IFNR -- NK | Lung.Epi (Aneuploid) and IFNG_Type_II_IFNR -- T CD8+ | Lung.Epi (Aneuploid): The persistent strong signaling between NK/CD8+ T cells and aneuploid tumor cells suggests ongoing attempts by the immune system to control tumor growth. However, this also indicates potential for adaptive immune resistance mechanisms within the tumor, such as induction of immune checkpoint molecules like PD-L1 on tumor cells.
• CD93_IFNGR1 -- Endo | Lung.Epi (Aneuploid): This novel interaction between endothelial cells (CD93) and tumor cells (IFNGR1) could suggest a role in tumor angiogenesis or immune modulation. CD93 is known to be involved in vascular integrity and inflammation, and its interaction with IFNGR1 might represent a mechanism by which tumor cells or the TME influences endothelial cell behavior.

Immune Checkpoint and Co-stimulation Anomalies

• Mechanism: Immune checkpoints are crucial regulators of immune responses, preventing autoimmunity. In cancer, tumor cells exploit these pathways to evade immune destruction. Co-stimulatory molecules (e.g., CD28, CD80/CD86) are critical for robust T cell activation. Aberrant expression of these molecules on tumor cells can lead to immune suppression or dysfunctional immune responses.

Key Tumor Interactions:

• CD80 CD28 -- Lung.Epi (Aneuploid) | B cell: This interaction is particularly interesting. While CD80 is typically found on antigen-presenting cells (APCs) to co-stimulate T cells via CD28, its strong expression and interaction on aneuploid lung epithelial cells with B cells in tumor conditions suggest a direct, potentially aberrant, regulatory role. Tumor cells can express CD80 and CD86 to regulate T cell responses, but this interaction with B cells might influence B cell activation, antibody production, or their role as APCs within the TME, potentially contributing to immune evasion or tumor progression. GeneCards: CD80
• LCK_CD8_receptor -- Lung.Epi (Aneuploid) | ILC: LCK is an intracellular kinase essential for T-cell receptor signaling, closely associated with the CD8 co-receptor. This interaction suggests a communication axis between aneuploid tumor cells and Innate Lymphoid Cells (ILCs), potentially modulating ILC function. ILCs are diverse and can either suppress or promote anti-tumor immunity, depending on their subtype and the microenvironment. The nature of this "CD8_receptor" on ILCs and its functional implication warrants further investigation.

Clinical or Translational Implications

The identified condition-specific cell-cell interactions, particularly those involving aneuploid lung epithelial cells in tumor samples, highlight several promising avenues for therapeutic intervention in Lung Cancer.

Targeting EGFR Signaling

• Therapeutic Potential: The prominent autocrine/paracrine EGFR signaling by aneuploid lung epithelial cells (EREG_EGFR -- Lung.Epi (Aneuploid) | Lung.Epi (Aneuploid)) underscores the continued importance of targeting EGFR in lung cancer, especially given the 'EGFR_mutation' metadata. Moreover, interactions with stromal cells (AREG_EGFR -- Lung.Epi (Aneuploid) | Mac, HBEGF_EGFR -- Lung.Epi (Aneuploid) | Fib) suggest that inhibiting EGFR could also modulate the pro-tumorigenic activities of macrophages and fibroblasts in the TME.
• Relevant Therapeutic Agents: First-, second-, and third-generation EGFR Tyrosine Kinase Inhibitors (TKIs) like Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Osimertinib are approved for EGFR-mutated non-small cell lung cancer (NSCLC) PubMed search: EGFR inhibitors NSCLC. Targeting EGFR ligands, such as monoclonal antibodies against AREG or HBEGF, could also be explored to disrupt these specific paracrine loops.

Modulating TGF-beta Pathway

• Therapeutic Potential: The widespread TGF-beta interactions, particularly TGFB1_TGFbeta_receptor2 -- Mac | Lung.Epi (Aneuploid) and TGFB3_TGFBR3 -- Lung.Epi (Aneuploid) | Fib, indicate that TGF-beta is a key driver of tumor progression, EMT, immune evasion, and fibrosis in the lung TME. Modulating this pathway could halt tumor progression, reduce metastatic potential, and sensitize tumors to other therapies by reversing immunosuppression and desmoplasia.
• Relevant Therapeutic Agents: TGF-beta pathway inhibitors are under clinical investigation for various cancers. These include small molecule inhibitors of TGF-beta receptor I (e.g., Galunisertib) and neutralizing antibodies against TGF-beta ligands (e.g., Fresolimumab, Lerdelimumab) or TGF-beta receptors. Combination therapies, especially with immune checkpoint inhibitors, are a promising strategy to overcome TGF-beta-mediated immunosuppression PubMed search: TGF-beta inhibitors lung cancer clinical trials.

Leveraging or Counteracting Interferon Signaling

• Therapeutic Potential: The persistence of IFN-gamma signaling (e.g., IFNG_Type_II_IFNR -- NK | Lung.Epi (Aneuploid)) suggests ongoing immune engagement. While IFN-gamma is broadly anti-tumorigenic, it can also induce adaptive resistance mechanisms in tumor cells (e.g., PD-L1 upregulation). Understanding these context-dependent roles is crucial. The CD93_IFNGR1 -- Endo | Lung.Epi (Aneuploid) interaction might uncover novel targets for anti-angiogenic therapy or immune modulation if CD93 contributes to tumor-supportive functions.
• Relevant Therapeutic Agents: Immunotherapies, such as PD-1/PD-L1 inhibitors (e.g., Pembrolizumab, Nivolumab, Atezolizumab), aim to unleash effective anti-tumor immune responses, often by enhancing IFN-gamma-mediated cytotoxicity. Investigating specific inhibitors or activators of CD93 could offer a novel approach if its role in promoting tumor growth or angiogenesis is confirmed.

Novel Immune Checkpoint Strategies

• Therapeutic Potential: The discovery of CD80 CD28 -- Lung.Epi (Aneuploid) | B cell interactions points to potential novel immune evasion mechanisms directly involving tumor cells. If tumor cell-expressed CD80 engages CD28 on B cells in a way that promotes pro-tumorigenic B cell functions or suppresses T cell activity via B cells, it could be a targetable pathway to enhance anti-tumor immunity. Similarly, understanding the LCK_CD8_receptor -- Lung.Epi (Aneuploid) | ILC interaction could lead to strategies to reprogram ILCs from pro-tumorigenic to anti-tumorigenic phenotypes.
• Relevant Therapeutic Agents: While direct targeting of tumor-expressed CD80/CD28 has not been a primary strategy, this finding warrants further investigation into its functional consequences. If it leads to immune suppression, novel immune checkpoint blockers or modulators specifically designed for this interaction could be developed. For ILC-mediated interactions, immunomodulatory agents that target specific ILC subsets or their signaling pathways could be explored to enhance anti-tumor responses.

15. Surfaceome Marker Expression in Lung Epithelial Cells of Lung Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis focuses on identifying and characterizing surfaceome markers expressed by Lung Epithelial cells from single-cell RNA-seq data. The goal is to delineate expression patterns across different conditions (Normal, Tumor(early), Tumor(adv)) and identify potential therapeutic targets. Markers were selected based on differential expression against a 'Normal' reference condition, specifically considering only cell surface proteins (surfaceome markers) with stringent fold change and non-zero percentage cutoffs. The interpretation distinguishes between established therapeutic targets and less well-characterized markers with potential clinical utility, providing biological context and relevant therapeutic information.

Visual Summary

The dot plot provides a comprehensive visualization of surfaceome gene expression and prevalence across various lung epithelial cell samples, grouped by condition and patient origin.

• Condition-Specific Expression Patterns: The plot clearly delineates three major expression patterns:
  • Normal-Enriched Markers: A set of genes, prominently clustered on the left side (e.g., FOLR1, PIGR, CLDN18, AQP4, ABCA3), show high mean expression (darker red color) and a high fraction of expressing cells (larger dot size) predominantly in 'Normal' samples (LUNG_NXX rows) and some 'Diploid LUNG_TXX' samples. These markers likely represent genes essential for normal lung epithelial function.
  • Tumor-Associated Upregulation: A significant cluster of genes towards the right side of the plot (e.g., MET, ERBB2, EGFR, EPHA2, PLAUR, CEACAM5, MUC4, ITGB4) exhibits robust upregulation in both 'Tumor(adv)' and 'Tumor(early)' samples. These markers are characterized by higher expression levels and/or a greater proportion of expressing cells in tumor samples compared to minimal or absent expression in most 'Normal' samples. This pattern strongly suggests their involvement in tumorigenesis and cancer progression.
  • Heterogeneity in Tumor Samples: Even within tumor conditions, heterogeneity in marker expression is evident. Some tumor samples show very high expression of specific markers, while others display moderate or low levels, reflecting the diverse molecular landscapes within lung cancer.
• Sample Clustering: Samples are hierarchically clustered on the y-axis. Normal samples (LUNG_NXX) tend to group together and exhibit distinct expression profiles from tumor samples. Tumor samples, including those identified as 'Diploid LUNG_TXX' and others, also show clustering, though some 'Diploid LUNG_TXX' samples share expression characteristics with normal samples for certain markers. The red boxes highlight specific regions of interest, emphasizing groups of samples or genes that show concerted expression changes. The lower red box, in particular, encloses a set of genes consistently upregulated in multiple tumor samples, reinforcing their potential as tumor-specific markers.

Biological Interpretation

The identification of these surfaceome markers offers critical insights into the molecular mechanisms driving lung cancer in epithelial cells. These proteins are often involved in cell communication, adhesion, and signaling, making them attractive candidates for therapeutic intervention.

Established Therapeutic Targets

1. EGFR (Epidermal Growth Factor Receptor)
   • Expression Pattern: EGFR is broadly and highly expressed in many tumor samples (both early and advanced), with lower levels in normal lung epithelial cells. This is consistent with its known role in lung cancer.
   • Signaling Pathways & Mechanisms: EGFR is a receptor tyrosine kinase crucial for cell proliferation, survival, migration, and differentiation. Upon ligand binding, it activates multiple downstream pathways, including the RAS/RAF/MEK/ERK cascade (mitogenesis) and the PI3K/AKT/mTOR pathway (survival and growth). Aberrant activation, often due to activating mutations or gene amplification, is a primary oncogenic driver in non-small cell lung cancer (NSCLC).
   • Relevant Therapeutic Agents: Multiple EGFR tyrosine kinase inhibitors (TKIs) are approved for EGFR-mutant NSCLC, such as gefitinib, erlotinib, afatinib, osimertinib, and dacomitinib. Monoclonal antibodies targeting EGFR, like cetuximab and necitumumab, are also used in certain cancer contexts.
   • Supporting Evidence: EGFR mutations are a well-established and actionable biomarker in NSCLC, guiding the use of EGFR-TKIs as first-line therapy for eligible patients PubMed Search: EGFR lung cancer targeted therapy.
   • GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=EGFR
2. MET (Mesenchymal-Epithelial Transition factor)
   • Expression Pattern: Upregulated in a subset of tumor samples, notably in both early and advanced stages, showing minimal expression in most normal cells.
   • Signaling Pathways & Mechanisms: MET is a receptor tyrosine kinase that, when activated by its ligand hepatocyte growth factor (HGF), initiates intracellular signaling cascades (e.g., PI3K/AKT, RAS/MAPK, STAT3) that promote cell proliferation, survival, motility, invasion, angiogenesis, and resistance to apoptosis. Dysregulation of MET, through gene amplification, exon 14 skipping mutations, or protein overexpression, can drive tumorigenesis and metastasis in NSCLC.
   • Relevant Therapeutic Agents: Several MET-targeting TKIs, including capmatinib, tepotinib, and savolitinib, are approved or in late-stage clinical development for NSCLC patients with MET exon 14 skipping mutations or MET amplification.
   • Supporting Evidence: MET alterations are recognized oncogenic drivers in NSCLC, with specific inhibitors demonstrating clinical efficacy in patients harboring these genetic changes PubMed Search: MET inhibition lung cancer.
   • GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=MET
3. ERBB2 (HER2 - Erb-B2 Receptor Tyrosine Kinase 2)
   • Expression Pattern: Shows increased expression in a distinct subset of tumor samples, particularly in advanced disease, with low expression in normal cells.
   • Signaling Pathways & Mechanisms: ERBB2, also known as HER2, is a member of the EGFR family that acts as a co-receptor, enhancing the signaling of other ERBB family members. While lacking a direct ligand, it forms heterodimers that activate key pro-survival and pro-proliferative pathways such as PI3K/AKT/mTOR and RAS/MAPK. ERBB2 amplification or activating mutations are oncogenic drivers in various cancers, including a small but significant fraction of NSCLC cases.
   • Relevant Therapeutic Agents: Antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-DXd) are effective in HER2-mutant NSCLC. Other agents, including HER2-targeted TKIs and monoclonal antibodies, are also under investigation.
   • Supporting Evidence: HER2 alterations, though less common than EGFR mutations, represent an important therapeutic target in NSCLC, with targeted therapies showing promising clinical responses PubMed Search: HER2 mutated lung cancer treatment.
   • GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=ERBB2

Less Well-Characterized Markers with Potential as Therapeutic Targets

1. CEACAM5 (Carcinoembryonic Antigen Related Cell Adhesion Molecule 5)
   • Expression Pattern: Exhibits strong upregulation in a large fraction of tumor cells in both early and advanced stages, largely absent in normal cells.
   • Signaling Pathways & Mechanisms: CEACAM5 is a cell adhesion glycoprotein involved in cell-cell interactions. In cancer, its overexpression can promote cell proliferation, survival, and immune evasion by modulating various signaling pathways. It can also contribute to resistance to chemotherapy.
   • Relevant Therapeutic Agents: CEACAM5 is being actively pursued as a target for antibody-drug conjugates (ADCs) due to its high and selective expression on cancer cells. Tusamitamab ravtansine, an anti-CEACAM5 ADC, is in clinical trials for NSCLC.
   • Supporting Evidence: CEACAM5 is a well-known tumor-associated antigen frequently overexpressed in various adenocarcinomas, including NSCLC, and its role as a therapeutic target is supported by preclinical and clinical studies with ADCs PubMed Search: CEACAM5 lung cancer ADC clinical trial.
   • GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CEACAM5
2. EPHA2 (Ephrin Receptor A2)
   • Expression Pattern: Shows increased expression in tumor epithelial cells, particularly in advanced stages, with minimal to no expression in normal cells.
   • Signaling Pathways & Mechanisms: EPHA2 is a receptor tyrosine kinase that interacts with ephrin-A ligands. Its role in cancer is complex, but often, its overexpression and aberrant activation promote cell proliferation, survival, migration, and angiogenesis. It can activate downstream signaling pathways like Rho GTPases and MAPK, influencing cytoskeletal dynamics and cell motility, thereby facilitating metastasis.
   • Relevant Therapeutic Agents: Monoclonal antibodies, ADCs, and small molecule inhibitors targeting EPHA2 are under preclinical and early clinical investigation for various cancers, including lung cancer.
   • Supporting Evidence: EPHA2 overexpression is frequently observed in lung cancer and correlates with disease progression, metastasis, and poor patient prognosis, highlighting its potential as a therapeutic target PubMed Search: EPHA2 lung cancer therapeutic.
   • GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=EPHA2
3. PLAUR (Plasminogen Activator, Urokinase Receptor)
   • Expression Pattern: Consistently upregulated in tumor cells from both early and advanced stages, showing low expression in normal epithelial cells.
   • Signaling Pathways & Mechanisms: PLAUR is a GPI-anchored cell surface receptor that binds urokinase plasminogen activator (uPA), initiating a proteolytic cascade that degrades the extracellular matrix. This process is critical for cell migration, invasion, and metastasis. PLAUR also signals directly or indirectly through integrins and other receptors, affecting cell adhesion, proliferation, and survival. Its overexpression promotes an aggressive tumor phenotype.
   • Relevant Therapeutic Agents: Inhibitors of the uPA/uPAR system and monoclonal antibodies targeting PLAUR are being investigated in preclinical and early clinical studies to block tumor invasion and metastasis.
   • Supporting Evidence: High PLAUR expression is strongly associated with increased tumor invasiveness, metastatic potential, and poor prognosis across a wide range of cancers, including NSCLC PubMed Search: PLAUR lung cancer invasion.
   • GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=PLAUR
4. MUC4 (Mucin 4, Cell Surface Associated)
   • Expression Pattern: Clearly overexpressed in tumor epithelial cells across both early and advanced conditions, with minimal to absent expression in normal cells.
   • Signaling Pathways & Mechanisms: MUC4 is a large transmembrane mucin glycoprotein that forms a protective layer on epithelial surfaces. In cancer, its overexpression contributes to tumor progression by masking tumor antigens, promoting cell proliferation and survival (often through interaction with ERBB2), enhancing cell motility, and conferring resistance to apoptosis and chemotherapy. It activates downstream signaling pathways like MAPK and PI3K/AKT.
   • Relevant Therapeutic Agents: Therapeutic strategies include monoclonal antibodies targeting MUC4 or ADCs. Disruption of MUC4-ERBB2 interactions is also a focus of drug development.
   • Supporting Evidence: MUC4 overexpression is a common feature in lung adenocarcinoma and is often associated with poor prognosis, metastasis, and resistance to therapy, making it a promising candidate for targeted therapeutic development PubMed Search: MUC4 lung adenocarcinoma prognosis.
   • GeneCards: https://www.genecards.org/cgi-bin/carddisp.pl?gene=MUC4

Clinical or Translational Implications

This analysis provides a valuable roadmap for advancing lung cancer diagnostics and therapeutics:

• Reinforcement of Existing Targets: The observed upregulation of EGFR, MET, and ERBB2 in tumor-origin lung epithelial cells underscores the continued clinical relevance of these established oncogenic drivers. This data supports the importance of routine molecular testing for these targets to guide personalized therapy for lung cancer patients.
• Identification of Novel Therapeutic Avenues: The distinct overexpression of surfaceome markers such as CEACAM5, EPHA2, PLAUR, and MUC4 in tumor cells suggests these proteins could serve as new therapeutic targets. Their cell surface localization makes them particularly amenable to antibody-based therapies, including antibody-drug conjugates (ADCs), which are designed to deliver cytotoxic agents selectively to cancer cells, minimizing systemic toxicity.
• Biomarker Development: These identified markers could be developed into diagnostic, prognostic, or predictive biomarkers. For instance, the expression levels of these markers could help identify early-stage disease, predict patient outcomes, or stratify patients who are more likely to respond to specific targeted therapies.
• Personalized Medicine: The observed heterogeneity in marker expression across tumor samples highlights the need for personalized treatment strategies. Future studies could explore the co-expression patterns of these markers to define specific tumor subpopulations that might benefit from combination therapies targeting multiple pathways.
• Liquid Biopsy Opportunities: As surface proteins, these markers might be detectable in liquid biopsies (e.g., circulating tumor DNA, circulating tumor cells, or extracellular vesicles). This could enable non-invasive monitoring of disease progression, therapeutic response, and minimal residual disease.

In conclusion, this analysis provides compelling evidence for several surfaceome proteins as actionable targets in lung cancer, ranging from well-validated drivers to promising novel candidates, offering significant potential for future clinical translation.

16. Macrophage Condition-Specific Surfaceome Markers in Lung Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers for Macrophages across Normal, advanced Tumor (Tumor(adv)), and early Tumor (Tumor(early)) lung tissue samples. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing (dot size) each marker within different samples. The goal is to highlight macrophage markers that are differentially expressed in the tumor microenvironment (TME) compared to normal tissue, providing insights into their biological roles and potential as therapeutic targets in Lung Cancer.

Visual Summary

The dot plot displays the expression of 74 macrophage surfaceome markers across 32 individual samples, categorized by their condition (Normal, Tumor(adv), Tumor(early)). Each row represents a sample, and each column represents a marker gene. The total number of cells per sample is indicated on the right-hand side.

Key Observations:

• Normal-specific Markers: A distinct cluster of markers (highlighted by the left red box) shows high expression and prevalence in macrophages from 'Normal' lung samples (e.g., LUNG_N06, LUNG_N09, LUNG_N08). These include genes like *TREM1, ADGRE5, SPN, ADAM17, CD46, SIRPB1, ICAM2, S1PR4, BST1*, and several others. These markers are largely absent or expressed at very low levels in macrophages from both 'Tumor(adv)' and 'Tumor(early)' samples, suggesting a significant alteration in macrophage phenotype within the tumor microenvironment.
• Tumor-associated Markers (Advanced and Early): Another prominent cluster of markers (highlighted by the middle and right red boxes) is characterized by increased expression and prevalence in macrophages from 'Tumor(adv)' and 'Tumor(early)' samples.
  • Some markers, such as *CD14, CD48, ICAM1, GPR183, TNFRSF1B, MPEG1, OD300A, CD93*, show strong enrichment in 'Tumor(adv)' samples.
  • Other markers like *CXCR4, CSF1R, FPR3, CD84, ABCA1, FCGR2B, C3AR1, NRP2, TTYH3, MMP14, ADAM9, SORL1* are notably upregulated in both 'Tumor(adv)' and 'Tumor(early)' conditions, often with higher intensity in advanced stages or a broader presence across tumor samples. This suggests their involvement from early stages of tumor development.
• Heterogeneity across Tumor Samples: While general patterns exist, there is notable heterogeneity in marker expression among individual tumor samples. For example, some 'Tumor(adv)' samples show stronger expression of certain markers than others (e.g., LUNG_T06 for *CSF1R* and *CXCR4*). This underscores the inter-patient variability in the macrophage immune landscape within lung cancer.
• Sample-Specific Expression: Some markers show expression in only a subset of tumor samples, indicating potential patient-specific or subtype-specific macrophage polarization and activation states.

Biological Interpretation

Macrophages are key components of the tumor microenvironment (TME) in Lung Cancer, with diverse functions that can either promote or suppress tumor growth. The observed differential expression of surface markers indicates distinct macrophage phenotypes in normal versus tumor conditions, reflecting their adaptation and functional specialization within the TME.

Markers Enriched in Normal Macrophages

The high expression of specific surface markers in normal lung macrophages, and their downregulation in tumor-associated macrophages (TAMs), points to a shift away from a homeostatic or healthy inflammatory phenotype.

TREM1 (Triggering Receptor Expressed on Myeloid cells 1):

• Signaling Pathways: TREM1 is an activating receptor that amplifies inflammatory responses triggered by Toll-like receptor (TLR) and C-type lectin receptor signaling. It signals through DAP12. GeneCards: TREM1
• Macrophage Role in TME: High TREM1 is typically associated with pro-inflammatory (M1-like) macrophages. Its downregulation in TAMs suggests a reduced pro-inflammatory response in the tumor, potentially indicating a shift towards an immunosuppressive or pro-tumorigenic (M2-like) phenotype that evades host immunity.
• Therapeutic Target Potential: Modulating TREM1 could influence the inflammatory state of macrophages. Upregulating TREM1 in TAMs might promote anti-tumor immunity.
• Relevant Therapeutic Agents: Peptides that block TREM1/DAP12 interaction have been investigated in inflammatory diseases, but direct therapeutic strategies for cancer are still emerging.

CD46 (Membrane Cofactor Protein):

• Signaling Pathways: CD46 is a complement regulatory protein that protects host cells from complement-mediated damage by acting as a cofactor for Factor I, which inactivates C3b and C4b. GeneCards: CD46
• Macrophage Role in TME: While broadly expressed, its differential expression on macrophages can reflect altered complement regulation in the TME. Its robust presence in normal macrophages might indicate a baseline level of immune regulation required for tissue homeostasis, which is altered in cancer.
• Therapeutic Target Potential: Altered CD46 expression on tumor cells or immune cells might influence their susceptibility to complement-dependent cytotoxicity (CDC) or antibody-dependent cellular phagocytosis (ADCP).
• Relevant Therapeutic Agents: Not a direct macrophage therapeutic target, but its modulation on tumor cells is explored for enhancing immunotherapy.

Markers Enriched in Tumor-Associated Macrophages (TAMs)

The upregulation of these markers in TAMs indicates their active participation in tumor progression, often through immune suppression, angiogenesis, and extracellular matrix remodeling.

CSF1R (Colony Stimulating Factor 1 Receptor):

• Signaling Pathways: CSF1R (also known as M-CSFR or CD115) is a receptor tyrosine kinase that binds Colony Stimulating Factor 1 (CSF1) and Interleukin-34 (IL-34). This binding activates downstream pathways like PI3K/Akt, MAPK/ERK, and STAT, critical for macrophage differentiation, survival, proliferation, and polarization. GeneCards: CSF1R
• Macrophage Role in TME: CSF1/CSF1R signaling is a central axis in the recruitment, survival, and differentiation of pro-tumorigenic TAMs, particularly M2-like phenotypes, in lung cancer. These TAMs promote tumor growth by fostering angiogenesis, immune suppression, and metastasis.
• Therapeutic Target Potential: CSF1R is a highly promising therapeutic target to deplete or reprogram TAMs and inhibit their pro-tumorigenic functions.
• Relevant Therapeutic Agents: Several CSF1R inhibitors (e.g., PLX3397/Pexidartinib, Cabiralizumab, Emactuzumab) are in clinical development for various cancers, including lung cancer, to reduce TAM abundance and improve responses to other therapies.

CXCR4 (C-X-C Motif Chemokine Receptor 4):

• Signaling Pathways: CXCR4 is a G protein-coupled receptor (GPCR) that primarily binds its ligand CXCL12 (SDF-1α). This interaction activates multiple downstream signaling pathways, including PI3K/Akt, MAPK/ERK, and Rho GTPases, leading to cell migration, proliferation, and survival. GeneCards: CXCR4
• Macrophage Role in TME: CXCR4 on TAMs mediates their recruitment to CXCL12-rich tumor areas. Once recruited, CXCR4-expressing TAMs can contribute to tumor growth, angiogenesis, and metastasis. It also plays a role in immunosuppression by attracting regulatory T cells.
• Therapeutic Target Potential: CXCR4 is a well-established therapeutic target in various cancers due to its critical role in tumor cell proliferation, survival, angiogenesis, and metastasis, and its involvement in immune cell trafficking.
• Relevant Therapeutic Agents: Plerixafor (AMD3100) is an FDA-approved CXCR4 antagonist used in stem cell mobilization. Other CXCR4 inhibitors are under investigation for their anti-cancer potential, often in combination with chemotherapy or immunotherapy.

MMP14 (Matrix Metallopeptidase 14 / MT1-MMP):

• Signaling Pathways: MMP14 is a membrane-anchored matrix metalloproteinase that degrades extracellular matrix (ECM) components like collagen, fibronectin, and laminin. It also activates other MMPs (e.g., pro-MMP2). Its activity is regulated by endogenous inhibitors (TIMPs). GeneCards: MMP14
• Macrophage Role in TME: TAMs often express high levels of MMP14, contributing significantly to ECM remodeling, which facilitates tumor cell invasion, metastasis, and angiogenesis. MMP14 also releases growth factors from the ECM, further promoting tumor progression.
• Therapeutic Target Potential: Inhibiting MMP14 activity in TAMs could impair tumor invasion and metastasis, making it an attractive target for anti-cancer therapy.
• Relevant Therapeutic Agents: Broad-spectrum MMP inhibitors have faced challenges in clinical trials, but selective MMP14 inhibitors are being explored to mitigate off-target effects and improve efficacy.

TNFRSF1B (Tumor Necrosis Factor Receptor Superfamily Member 1B / TNFR2):

• Signaling Pathways: TNFRSF1B is a receptor for TNF-alpha. Unlike TNFRSF1A (TNFR1) which often mediates apoptosis, TNFRSF1B signaling typically promotes cell survival, proliferation, and inflammatory responses via pathways like NF-κB and MAPK. GeneCards: TNFRSF1B
• Macrophage Role in TME: High expression of TNFRSF1B on TAMs in the TME can contribute to their pro-tumorigenic and immunosuppressive functions. It can promote the survival and expansion of TAMs and other suppressive immune cells, creating an environment permissive for tumor growth.
• Therapeutic Target Potential: Selective blockade of TNFRSF1B might reduce TAM survival and/or reprogram their function towards anti-tumor activity without broadly suppressing TNF-alpha signaling which has dual roles.
• Relevant Therapeutic Agents: TNFR2-specific antibodies or antagonists are being explored as potential immunotherapeutic agents in various cancers.

CD14 (Lipopolysaccharide Receptor):

• Signaling Pathways: CD14 acts as a co-receptor for Toll-like receptor 4 (TLR4), mediating responses to lipopolysaccharide (LPS) and other pathogen-associated molecular patterns (PAMPs), leading to activation of NF-κB and production of inflammatory cytokines. It can exist in both membrane-bound (mCD14) and soluble (sCD14) forms. GeneCards: CD14
• Macrophage Role in TME: CD14 expression on TAMs can indicate their activation status and involvement in inflammatory responses within the TME. While often associated with M1-like (pro-inflammatory) macrophages in acute inflammation, chronic exposure to certain TME signals can lead to CD14+ macrophages adopting pro-tumorigenic M2-like phenotypes, contributing to immune suppression and tumor progression, particularly in settings of chronic inflammation in lung cancer.
• Therapeutic Target Potential: Modulating CD14/TLR4 signaling on TAMs could alter their polarization and dampen pro-tumorigenic inflammatory pathways.
• Relevant Therapeutic Agents: Agents targeting TLR4 signaling or CD14 are being investigated in sepsis and inflammatory diseases, with potential for repurposing in cancer.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers on macrophages provides valuable insights with significant clinical and translational implications for Lung Cancer.

Diagnostic and Prognostic Biomarkers:

• Markers like *CSF1R, CXCR4, MMP14, TNFRSF1B*, which are highly expressed in TAMs from both early and advanced tumor conditions, could serve as diagnostic or prognostic biomarkers for Lung Cancer. Their presence or abundance on tumor-infiltrating macrophages could indicate tumor progression, metastatic potential, or patient response to therapy.
• The shift from Normal-associated markers (e.g., *TREM1, CD46*) to Tumor-associated markers might represent a "macrophage reprogramming signature" that could be tracked.

Therapeutic Targets for Macrophage Reprogramming/Depletion:

• CSF1R: Given its critical role in TAM biology, CSF1R is a prime therapeutic target. Inhibitors aim to deplete TAMs or reprogram them into anti-tumorigenic phenotypes. Clinical trials in Lung Cancer are evaluating CSF1R inhibitors, often in combination with chemotherapy or immune checkpoint blockade, to overcome immune suppression.
• CXCR4: Targeting the CXCL12-CXCR4 axis could disrupt macrophage recruitment to the TME and inhibit pro-tumorigenic activities, making it a viable target for anti-metastatic strategies in lung cancer.
• MMP14: Inhibiting MMP14 on TAMs could reduce ECM degradation, thereby limiting tumor invasion and metastasis, which are major challenges in Lung Cancer treatment.
• TNFRSF1B: Selectively blocking TNFRSF1B might alleviate immune suppression mediated by TAMs, enhancing the efficacy of other immunotherapies.

Personalized Medicine Approaches:

• The observed heterogeneity in marker expression across different tumor samples suggests that personalized approaches might be necessary. Identifying which specific macrophage markers are highly expressed in a patient's tumor could guide the selection of targeted therapies.
• For example, patients with high *CSF1R* expression on their TAMs might benefit most from CSF1R inhibitors.

Monitoring Treatment Response:

• Changes in the expression profiles of these markers on circulating monocytes or tumor biopsies could be used to monitor the efficacy of therapies targeting TAMs or to predict patient response to immunotherapy.

In summary, the distinct surfaceome profiles of macrophages in normal versus tumor conditions highlight the dynamic role of these cells in Lung Cancer progression. Targeting these specific surface markers represents a promising avenue for developing novel immunotherapeutic strategies to reprogram the tumor microenvironment and improve patient outcomes.

17. Fibroblast Condition-Specific Surfaceome Markers in Lung Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers for Fibroblasts in human lung tissue, comparing Normal samples to early-stage Tumor (Tumor(early)) samples. The markers were selected using differential gene expression analysis against a reference (Normal), with a focus on surface-expressed proteins. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) across individual samples, grouped by condition. This approach aims to reveal phenotypic shifts in Fibroblast populations within the tumor microenvironment (TME) and identify potential therapeutic targets.

Visual Summary

The dot plot clearly delineates two distinct populations of Fibroblast markers based on their expression profiles across Normal and Tumor(early) conditions.

1. Normal Condition-Specific Markers (e.g., GPNMB, TSPAN8, SCARA5, GAS1, LEPR, PTPRS, CD34, CDH11): These markers show high mean expression (darker red dots) and a high fraction of expressing cells (larger dot sizes) in the Fibroblast populations from Normal lung samples (LUNG_N31, LUNG_N18, LUNG_N30, LUNG_N34, LUNG_N09, LUNG_N19). Conversely, their expression is largely absent or significantly reduced in Tumor(early) samples, indicated by smaller, lighter-colored, or absent dots. This suggests a unique signature for homeostatic or non-tumor-activated fibroblasts.
2. Tumor(early) Condition-Specific Markers (e.g., PDGFRB, ANTXR1, MMP14, FAP, ITGAV, NOTCH2, VCAM1, FZD1): A broad array of surface markers demonstrates strong and prevalent expression in Fibroblasts from early tumor samples (LUNG_T28, LUNG_T06, LUNG_T08, LUNG_T19, LUNG_T18, LUNG_T31, LUNG_T30) but are largely absent or minimally expressed in Normal samples. These markers include classic indicators of activated cancer-associated fibroblasts (CAFs), such as FAP and PDGFRB, alongside various matrix metalloproteinases, integrins, and signaling receptors. Their robust and consistent upregulation in early tumor stages highlights a significant phenotypic reprogramming of fibroblasts in the presence of malignancy.

Overall, the plot effectively illustrates a dramatic shift in fibroblast surfaceome composition as these cells transition from a normal tissue state to an early tumor-associated state, underscoring their active role in shaping the evolving tumor microenvironment.

Biological Interpretation

The observed differential expression of surfaceome markers in Fibroblasts between normal and early tumor conditions provides critical insights into their activation state and function within the lung cancer microenvironment. This shift indicates the emergence of Cancer-Associated Fibroblasts (CAFs), which are known to significantly contribute to tumor progression.

Below, we detail key markers prominently expressed in Tumor(early) Fibroblasts:

FAP (Fibroblast Activation Protein Alpha)

• Associated Signaling Pathways: FAP, a serine protease, can cleave various extracellular matrix (ECM) components and peptide substrates, influencing matrix remodeling and growth factor bioavailability. It interacts with the Wnt/β-catenin pathway and can modulate TGF-β signaling.
• Role in TME: FAP is a canonical marker of CAFs. In the lung cancer TME, FAP-positive fibroblasts promote tumor growth, invasion, and metastasis by remodeling the ECM, creating an immunosuppressive environment, and supporting angiogenesis. They also influence immune cell infiltration and function.
• Potential as Therapeutic Target: FAP is highly expressed on CAFs in most solid tumors, including lung cancer, but is minimally expressed in normal adult tissues, making it an attractive therapeutic target.
• Relevant Therapeutic Agents: FAP-targeted therapies include FAP-specific antibodies (e.g., sibrotuzumab, though efficacy in monotherapy was limited), FAP-targeting CAR T-cells, FAP-radioconjugates for imaging and therapy, and FAP-prodrug activators.
• Other Pertinent Information: FAP expression is correlated with poor prognosis in various cancers and its targeting has shown promising preclinical results in reducing tumor growth and enhancing immunotherapy efficacy.
  • GeneCards: FAP
  • PubMed Search: FAP Cancer Associated Fibroblasts Lung Cancer Therapeutics

PDGFRB (Platelet-Derived Growth Factor Receptor Beta)

• Associated Signaling Pathways: PDGFRB is a receptor tyrosine kinase that, upon binding to its ligand (PDGF), initiates downstream signaling cascades including PI3K/Akt, MAPK/ERK, and STAT pathways, leading to cell proliferation, survival, migration, and ECM production.
• Role in TME: PDGF/PDGFRB signaling is a crucial axis for fibroblast activation and survival in the TME. CAFs in lung cancer often exhibit elevated PDGFRB, promoting their proliferation and differentiation, and contributing to desmoplasia and angiogenesis.
• Potential as Therapeutic Target: PDGFRB is a well-established therapeutic target in various fibrotic diseases and cancers.
• Relevant Therapeutic Agents: Tyrosine kinase inhibitors (TKIs) that target PDGFRB, such as imatinib, sunitinib, and nintedanib, are clinically available and used in various contexts. Nintedanib, for instance, is approved for idiopathic pulmonary fibrosis and certain lung cancers, partly due to its anti-fibrotic and anti-angiogenic properties via PDGFR inhibition.
  • GeneCards: PDGFRB
  • PubMed Search: PDGFRB Lung Cancer Fibroblast Inhibitors

MMP14 (Matrix Metalloproteinase 14 / MT1-MMP)

• Associated Signaling Pathways: MMP14 is a membrane-bound matrix metalloproteinase that degrades various ECM components (e.g., collagen, fibronectin) and activates other proteases (e.g., pro-MMP2). Its activity is regulated by endogenous inhibitors (TIMPs) and cell surface interactions.
• Role in TME: In the lung cancer TME, MMP14 expressed by CAFs plays a critical role in ECM remodeling, facilitating tumor cell invasion, intravasation, and metastasis. It also promotes angiogenesis and influences immune cell trafficking by modifying the local extracellular environment.
• Potential as Therapeutic Target: As a key enzyme in matrix degradation, MMP14 is an attractive target for inhibiting tumor invasion and metastasis.
• Relevant Therapeutic Agents: Broad-spectrum MMP inhibitors initially showed limited success due to toxicity and lack of specificity. However, more selective MMP14 inhibitors are under investigation, aiming to specifically block its pro-tumorigenic functions.
  • GeneCards: MMP14
  • PubMed Search: MMP14 Cancer Associated Fibroblasts Lung Cancer

Integrins (e.g., ITGAV, ITGB5, ITGA1, ITGA8)

• Associated Signaling Pathways: Integrins are heterodimeric cell surface receptors that mediate cell-ECM and cell-cell adhesion. Upon ligand binding, they activate intracellular signaling pathways (e.g., FAK, Src, PI3K/Akt, MAPK) that regulate cell survival, proliferation, migration, and differentiation.
• Role in TME: CAFs heavily rely on integrins to interact with the altered ECM in the TME. Specific integrin heterodimers (e.g., αVβ3, αVβ5, αVβ6) are often upregulated in CAFs and contribute to their adhesion, migration, and contractility, which are essential for ECM remodeling, angiogenesis, and tumor cell invasion. ITGAV, in particular, often pairs with different beta subunits (like ITGB5, ITGB3, ITGB6) to form receptors for various ECM proteins like vitronectin, fibronectin, and latent TGF-β.
• Potential as Therapeutic Target: Integrins represent valuable targets due to their critical roles in cancer cell and CAF biology, including adhesion, migration, and angiogenesis.
• Relevant Therapeutic Agents: Integrin antagonists, such as cilengitide (αVβ3 and αVβ5 inhibitor), have been tested in clinical trials for various cancers, including lung cancer, with varying success. Further research is ongoing to develop more specific and effective integrin-targeting agents.
  • GeneCards: ITGAV
  • PubMed Search: Integrin Cancer Associated Fibroblasts Lung Cancer Therapeutics

VCAM1 (Vascular Cell Adhesion Molecule 1)

• Associated Signaling Pathways: VCAM1 is an adhesion molecule typically found on endothelial cells, but its expression can be induced on other cell types, including fibroblasts, by inflammatory cytokines (e.g., TNF-α, IL-1β). It mediates cell adhesion by binding to integrins, particularly VLA-4 (α4β1 integrin), on leukocytes.
• Role in TME: VCAM1 on CAFs can contribute to the recruitment and retention of immune cells (e.g., macrophages, lymphocytes) and potentially tumor cells within the TME, influencing immune evasion and metastasis. Its presence can indicate an inflammatory CAF phenotype.
• Potential as Therapeutic Target: Targeting VCAM1 could disrupt tumor-stromal and tumor-immune interactions, thereby impeding tumor progression and metastasis.
• Relevant Therapeutic Agents: Anti-VCAM1 antibodies or inhibitors of VCAM1-VLA-4 interaction could potentially block these adhesive processes.
  • GeneCards: VCAM1
  • PubMed Search: VCAM1 Cancer Associated Fibroblasts Lung Cancer

NOTCH2

• Associated Signaling Pathways: NOTCH2 is a receptor in the Notch signaling pathway, a highly conserved cell-to-cell communication system critical for embryonic development and adult tissue homeostasis. Upon ligand binding (e.g., Jagged or Delta-like ligands), Notch receptors undergo proteolytic cleavage, releasing an intracellular domain that translocates to the nucleus to regulate gene expression.
• Role in TME: Notch signaling is frequently aberrantly activated in various cancers, including lung cancer, and plays a role in CAF activation. NOTCH2 activation in CAFs can promote their proliferation, survival, and expression of pro-tumorigenic factors, contributing to the aggressive phenotype of the TME.
• Potential as Therapeutic Target: Inhibiting Notch signaling, including NOTCH2, is an area of active research for cancer therapy.
• Relevant Therapeutic Agents: Gamma-secretase inhibitors (GSIs) are a class of drugs that broadly inhibit Notch signaling by blocking the cleavage of Notch receptors. Several GSIs have been evaluated in clinical trials for various cancers.
  • GeneCards: NOTCH2
  • PubMed Search: NOTCH2 Cancer Associated Fibroblasts Lung Cancer Inhibitors

Clinical or Translational Implications

The identification of distinct surfaceome marker profiles in Fibroblasts across normal and early tumor stages holds significant clinical and translational value for Lung Cancer.

1. Biomarker Discovery for Early Detection and Prognosis: The specific upregulation of markers like FAP, PDGFRB, and MMP14 in early tumor-associated fibroblasts could serve as early diagnostic biomarkers for lung cancer progression or as prognostic indicators for patient outcomes. Detection of these markers, perhaps via liquid biopsy or specific imaging agents, could enable earlier intervention.
2. Therapeutic Targeting of CAFs: The prominent and specific expression of these surface markers on CAFs, with limited expression in normal cells, presents opportunities for targeted therapies.
   • Direct Targeting: Agents like FAP-targeted antibodies, CAR T-cells, or radioconjugates could specifically eliminate or inactivate CAFs, thereby disrupting the pro-tumorigenic microenvironment.
   • Pathway Inhibition: Targeting key signaling pathways active in CAFs (e.g., PDGFRB with TKIs, Notch with GSIs) could inhibit CAF activation, proliferation, and their support for tumor growth.
   • ECM Remodeling: Inhibiting enzymes like MMP14 could reduce matrix degradation and hinder tumor invasion and metastasis, potentially making the tumor more accessible to other therapies.
3. Enhancing Immunotherapy Efficacy: CAFs are known to contribute to immunosuppression in the TME. By targeting CAF-specific markers (e.g., FAP, VCAM1), it may be possible to reprogram the TME, reduce immunosuppression, and enhance the efficacy of immune checkpoint inhibitors or other immunotherapies in lung cancer patients.
4. Monitoring Treatment Response: Changes in the expression of these CAF markers could potentially be used to monitor treatment response and detect residual disease or recurrence, providing a dynamic assessment of therapeutic interventions.

Overall, these findings underscore the critical role of Fibroblasts in lung cancer development and highlight a rich landscape of surfaceome targets for novel diagnostic and therapeutic strategies, particularly in the context of early disease intervention.

18. Condition-Specific Surfaceome Markers in CD4+ T Cells in Lung Cancer

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers in CD4+ T cells, comparing expression patterns across Normal, Tumor (advanced), and Tumor (early) conditions in Lung tissue. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) for individual samples grouped by their condition. Markers were selected based on differential expression against a 'Normal' reference condition, focusing on surfaceome genes and applying specific cutoffs for non-zero percentage score and fold change, with at most 40 markers per condition considered. The analysis aims to uncover distinct immunological states of CD4+ T cells in the tumor microenvironment (TME) of Lung Cancer.

Visual Summary

The dot plot, titled "T cell CD4+ condition-specific markers," effectively categorizes samples into Normal, Tumor(adv), and Tumor(early) conditions, showcasing distinct marker expression profiles within each group.

• Sample Clustering: Samples from Normal conditions (e.g., LUNG_N01 to LUNG_N34) largely cluster together and exhibit a shared expression pattern for several markers. Similarly, samples from Tumor(adv) (e.g., EBUS_49 to EBUS_06) and Tumor(early) (e.g., LUNG_T19 to LUNG_T34) tend to group, indicating condition-specific immunological landscapes.
• Normal-Associated Markers: Genes such as *HLA-DRA*, *HLA-DRB1*, *HLA-DQA1*, *ADGRE5*, *MYADM*, *PIK3IP1*, *SELL*, and *CD164* show consistently high mean expression (dark red dots) and high fraction of positive cells (large dots) across most normal samples. *CD27* also exhibits high expression in normal samples, generally appearing downregulated in tumor conditions compared to normal, despite being listed in the header under both normal and tumor conditions.
• Tumor-Associated Markers: In contrast, markers like *CD7*, *BST1*, *TNFRSF14*, *EVI2A*, and *ICOS* show elevated expression primarily within the Tumor(adv) and Tumor(early) samples. For these markers, the dots are generally darker red and larger in tumor samples compared to normal samples, indicating higher expression and prevalence in tumor-infiltrating CD4+ T cells.
• Variability within Tumor Conditions: While some markers are broadly expressed across tumor samples, there is noticeable heterogeneity. For instance, some tumor samples show higher expression of certain tumor-associated markers than others, reflecting inter-patient variability in immune responses within the TME.

Biological Interpretation

The identified surfaceome markers provide insights into the functional states and interactions of CD4+ T cells in the context of Lung Cancer. The distinctions between normal and tumor-associated CD4+ T cells highlight potential mechanisms of immune regulation and dysregulation in the TME.

Markers Enriched in Normal CD4+ T Cells (Compared to Tumor Conditions)

These markers suggest an active role in immune surveillance and maintenance of homeostasis in healthy lung tissue. Their downregulation in tumor conditions may indicate immune evasion or T cell dysfunction.

HLA-DRA, HLA-DRB1, HLA-DQA1 (MHC Class II molecules)

• Associated Signaling Pathways: Antigen presentation pathway, T cell receptor (TCR) signaling, co-stimulation. These molecules are crucial for presenting peptide antigens to CD4+ T cells, leading to their activation, proliferation, and differentiation into helper T cells.
• Role in TME: High expression in normal CD4+ T cells suggests a robust capacity for antigen presentation, potentially by T cells acting as antigen-presenting cells (APCs) themselves, or indicative of a resting/naïve phenotype. The observed downregulation in tumor conditions implies impaired antigen presentation, a common immune evasion strategy by tumors, contributing to an immunosuppressive TME. This could also reflect a shift in T cell subsets or activation states.
• Potential as Therapeutic Target & Agents: While not direct therapeutic targets on T cells, maintaining or restoring MHC-II expression on APCs (and potentially T cells) can enhance anti-tumor immunity. Strategies focus on improving antigen presentation (e.g., vaccination, oncolytic viruses, certain checkpoint inhibitors targeting APC function) or direct activation of MHC-II on tumor cells.
• References: GeneCards: HLA-DRA, HLA-DRB1, HLA-DQA1.

ADGRE5 (CD97)

• Associated Signaling Pathways: Adhesion G protein-coupled receptor (GPCR) signaling. Involved in cell-cell adhesion, cell migration, and immune cell interactions, often through binding to CD55 (DAF).
• Role in TME: Its enrichment in normal CD4+ T cells might indicate a role in maintaining immune homeostasis or specific trafficking patterns in healthy lung. In cancer, ADGRE5 can have context-dependent roles, sometimes promoting immune cell migration, other times contributing to pro-tumorigenic processes.
• Potential as Therapeutic Target & Agents: Modulating ADGRE5 could impact immune cell adhesion and migration, potentially influencing T cell infiltration or retention within the TME.
• References: GeneCards: ADGRE5.

MYADM (Myeloid-associated differentiation marker)

• Associated Signaling Pathways: Involved in cell differentiation and potentially cell adhesion. Its precise signaling on T cells is less characterized than on myeloid cells.
• Role in TME: Elevated expression in normal CD4+ T cells suggests a role in maintaining specific differentiation states or functions within healthy lung immune cells. Its exact contribution to the TME of lung cancer requires further investigation.
• References: GeneCards: MYADM.

CD27

• Associated Signaling Pathways: Tumor Necrosis Factor Receptor Superfamily (TNFRSF) member. Binds its ligand CD70, providing co-stimulatory signals essential for T cell activation, proliferation, survival, and the development of memory T cells.
• Role in TME: In normal conditions, high CD27 expression is typically found on naïve and central memory T cells, indicating an unexhausted or memory state capable of mounting robust immune responses. Its general downregulation in tumor-associated CD4+ T cells (as observed visually) might suggest T cell exhaustion or differentiation into effector cells that have lost CD27 expression, a common feature of chronic antigen stimulation in the TME.
• Potential as Therapeutic Target & Agents: Agonistic antibodies targeting CD27 (e.g., Varlilumab) have been developed to enhance anti-tumor T cell responses by providing co-stimulation.
• References: GeneCards: CD27.

PIK3IP1 (FOAP1)

• Associated Signaling Pathways: Negative regulator of the PI3K/Akt signaling pathway, which is critical for T cell activation, survival, and differentiation.
• Role in TME: Its upregulation in normal CD4+ T cells suggests a mechanism to fine-tune or limit PI3K signaling, contributing to immune homeostasis and preventing over-activation. Downregulation in tumor contexts could lead to dysregulated PI3K pathway activity, affecting T cell function and potentially contributing to immune suppression or altered differentiation.
• Potential as Therapeutic Target & Agents: Modulating PIK3IP1 could impact T cell activation and function, offering a potential avenue for restoring appropriate immune responses, though direct therapeutic agents are not yet prominent.
• References: GeneCards: PIK3IP1.

SELL (CD62L)

• Associated Signaling Pathways: Adhesion molecule (L-selectin family). Involved in lymphocyte homing to secondary lymphoid organs (e.g., lymph nodes) and site of inflammation.
• Role in TME: High expression on naïve and central memory T cells. Essential for T cell trafficking. Its enrichment in normal CD4+ T cells aligns with immune surveillance in healthy tissue, suggesting a less differentiated or non-effector state. Loss of CD62L can indicate effector or exhausted T cells that have exited lymph nodes and migrated to peripheral tissues, including the tumor.
• Potential as Therapeutic Target & Agents: While not a direct therapeutic target on T cells in cancer, CD62L expression is a critical marker for distinguishing T cell subsets and understanding their migratory potential, which can be indirectly modulated through chemokine receptor targeting.
• References: GeneCards: SELL.

CD164

• Associated Signaling Pathways: Sialomucin, involved in cell adhesion, migration, and hematopoietic stem cell biology.
• Role in TME: Its role on CD4+ T cells in the TME is less clearly defined but may contribute to cell-cell interactions or migration properties of T cells. Its enrichment in normal cells could reflect a baseline adhesive phenotype.
• Potential as Therapeutic Target & Agents: Limited direct therapeutic target implications, but understanding its role in T cell dynamics might reveal indirect modulation strategies.
• References: GeneCards: CD164.

Markers Enriched in Tumor-Associated CD4+ T Cells (Compared to Normal Condition)

These markers indicate specific activation states, exhaustion, or regulatory functions acquired by CD4+ T cells within the immunosuppressive TME of Lung Cancer.

CD7

• Associated Signaling Pathways: Glycoprotein involved in cell adhesion and co-stimulation, although its precise signaling pathways on mature T cells are less well-defined compared to other co-stimulatory molecules. It may participate in early T cell activation and survival.
• Role in TME: Its consistent upregulation in both early and advanced tumor CD4+ T cells suggests a specific T cell phenotype associated with tumor presence. This could include activated T cells, or potentially certain subsets of regulatory T cells (Tregs) or exhausted T cells with altered activation/survival signals.
• Potential as Therapeutic Target & Agents: While less commonly a direct therapeutic target for T cells in solid tumors, its expression patterns can serve as a diagnostic or prognostic marker for specific T cell populations.
• References: GeneCards: CD7.

BST1 (CD157)

• Associated Signaling Pathways: Ectoenzyme with ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities, involved in calcium signaling. Functions as an adhesion molecule.
• Role in TME: Upregulation in tumor-associated CD4+ T cells might suggest a state of activation, differentiation, or immune modulation within the TME. Altered calcium signaling can profoundly impact T cell function, including proliferation, cytokine production, and anergy/exhaustion.
• Potential as Therapeutic Target & Agents: Modulating BST1's enzymatic activity or adhesive properties could influence T cell responses in the TME, but direct therapeutic targeting is still in early stages.
• References: GeneCards: BST1.

TNFRSF14 (HVEM)

• Associated Signaling Pathways: Tumor Necrosis Factor Receptor Superfamily member. Interacts with various ligands including LIGHT, BTLA, and CD160, playing a complex role in modulating T cell activation and inhibition. LIGHT-HVEM interaction is co-stimulatory, while BTLA-HVEM interaction is co-inhibitory.
• Role in TME: Upregulation in tumor CD4+ T cells suggests their involvement in intricate checkpoint signaling within the TME. Depending on the availability of its ligands, HVEM can either promote T cell activation (e.g., via LIGHT) or contribute to T cell exhaustion and immune suppression (e.g., via BTLA on T cells or other immune cells). Its role often points to an attempt at immune regulation or chronic activation leading to exhaustion.
• Potential as Therapeutic Target & Agents: As a checkpoint molecule, TNFRSF14 and its ligands are significant targets for immunotherapy. Agonistic antibodies targeting HVEM (or its ligand LIGHT) could potentially enhance anti-tumor immunity by providing co-stimulation. Conversely, blocking the BTLA-HVEM axis might release T cells from inhibitory signals.
• References: GeneCards: TNFRSF14.

EVI2A

• Associated Signaling Pathways: Less well-defined. Located within an intron of the *RARB* gene (Retinoic Acid Receptor Beta) and implicated in cell growth and differentiation.
• Role in TME: Its upregulation in tumor-infiltrating CD4+ T cells suggests an altered transcriptional program in these cells, potentially influencing their differentiation or functional state. The precise mechanisms and implications in the TME require further research.
• Potential as Therapeutic Target & Agents: Limited direct therapeutic implications, but its identification highlights unique molecular changes in tumor-associated T cells.
• References: GeneCards: EVI2A.

ICOS (CD278)

• Associated Signaling Pathways: Inducible T cell Co-Stimulator, a member of the CD28 family. Binds to its ligand ICOSL (B7-H2) on APCs, providing crucial co-stimulatory signals for effector and regulatory T cell function, particularly for T follicular helper (Tfh) cells and certain subsets of regulatory T cells (Tregs). It promotes T cell proliferation, survival, and cytokine production.
• Role in TME: Upregulation of ICOS is frequently observed on activated and functionally relevant T cells within the TME, including anti-tumor effector T cells and immunosuppressive Tregs. In Lung Cancer, ICOS+ T cells can be associated with both anti-tumor responses and immune suppression, depending on the specific T cell subset expressing it (e.g., ICOS+ effector T cells vs. ICOS+ Tregs). Its increased expression in both early and advanced tumor conditions points to active, albeit potentially dysregulated, immune responses.
• Potential as Therapeutic Target & Agents: ICOS is a significant immunotherapeutic target. Agonistic antibodies targeting ICOS (e.g., JTX-2011) are under clinical investigation to enhance anti-tumor T cell immunity, while blocking antibodies or strategies to deplete ICOS+ Tregs could also be explored to modulate immune suppression.
• References: GeneCards: ICOS.

Clinical or Translational Implications

The distinct surfaceome marker profiles observed in CD4+ T cells from Normal versus Tumor (early and advanced) Lung Cancer patients offer valuable clinical and translational insights:

1. Biomarker Development: The identified markers can serve as potential diagnostic or prognostic biomarkers for Lung Cancer. For instance, a decrease in MHC Class II molecules (HLA-DRA/DRB1/DQA1) or CD27 on circulating or tumor-infiltrating CD4+ T cells could indicate tumor presence or disease progression. Conversely, elevated expression of *ICOS* or *TNFRSF14* might identify distinct populations of tumor-infiltrating lymphocytes with specific functional states.
2. Therapeutic Target Identification: Markers predominantly expressed in tumor-associated CD4+ T cells, such as *ICOS* and *TNFRSF14*, represent promising immunotherapeutic targets.
   • ICOS agonists: Given ICOS's role in T cell activation and proliferation, agonistic antibodies could be explored to enhance the anti-tumor response of CD4+ T cells, potentially synergizing with existing checkpoint inhibitors.
   • TNFRSF14 (HVEM) modulators: The complex role of TNFRSF14 in immune co-stimulation and co-inhibition makes it an intriguing target. Therapies could aim to either activate pro-inflammatory pathways (e.g., via LIGHT-HVEM) or block inhibitory interactions (e.g., via BTLA-HVEM) to reshape the TME.
3. Understanding Immune Evasion: The downregulation of MHC Class II molecules in tumor CD4+ T cells suggests a mechanism of immune evasion or altered antigen presentation capacity in the TME. Strategies to restore or enhance antigen presentation could improve the efficacy of immunotherapies.
4. T Cell Phenotyping: These markers provide a refined understanding of CD4+ T cell heterogeneity within the Lung Cancer TME. This can guide the development of adoptive T cell therapies by selecting or engineering specific T cell subsets with desired functional properties. For example, identifying the ratio of CD27-high (less exhausted) vs. ICOS-high (activated/regulatory) T cells could inform treatment strategies.
5. Monitoring Treatment Response: Changes in the expression of these markers on CD4+ T cells could potentially be used to monitor patient responses to various cancer treatments, including chemotherapy, radiation, and immunotherapy.

19. Differential Expression of Cell Cycle Genes in Lung Epithelial Cells Across Lung Cancer Stages

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the expression of a curated panel of cell cycle pathway genes within Lung Epithelial cells across different conditions: 'Normal', 'Tumor(early)', and 'Tumor(adv)' (advanced tumor). The expression is quantified as the "expressing cell fraction (sample)", which represents the proportion of cells within each sample that express a given gene. The objective is to identify statistically significant differences in the expression of these genes across these conditions, providing insight into cell cycle dysregulation in lung cancer.

Visual Summary

The box plots display the distribution of expressing cell fractions for 24 selected cell cycle-related genes across the three conditions. Each dot represents a sample. Key observations include:

• Upregulation in Tumor Conditions: A substantial number of genes, particularly those associated with cell cycle progression and DNA replication (e.g., MCM4, CCNB1, MCM7, E2F1, CDK7, BUB3, WEE1, YWHAQ, ANAPC1, MAD2L2, CDK4, MCM3), show significantly higher expressing cell fractions in both 'Tumor(early)' and 'Tumor(adv)' conditions compared to 'Normal' lung epithelial cells.
• Progression-Related Trends: For several genes (e.g., MCM4, CCNB1, MCM7), the expressing cell fraction appears to increase with tumor progression, often being highest in 'Tumor(adv)', intermediate in 'Tumor(early)', and lowest in 'Normal'. Many of these differences between 'Tumor(adv)' and 'Tumor(early)' are also statistically significant or show strong trends (e.g., MCM4, CCNB1, MCM7).
• Downregulation in Tumor Conditions: Some genes, like GADD45B and CUL1, show a significantly *lower* expressing cell fraction in tumor conditions compared to 'Normal', particularly GADD45B in both tumor stages and CUL1 in 'Tumor(adv)'.
• Complex or Stage-Specific Patterns: Genes such as RB1, EP300, TP53, and SMAD4 exhibit more nuanced or stage-dependent expression patterns, where differences are not uniformly higher or lower across all tumor stages compared to normal, or may only be significant in one tumor stage. For instance, RB1, TP53, EP300, and SMAD4 show higher expression in 'Tumor(early)' compared to 'Normal', but this pattern is not sustained or is less pronounced in 'Tumor(adv)'.

Biological Interpretation

The observed differential expression patterns of cell cycle genes in Lung Epithelial cells provide strong biological insights into lung cancer pathogenesis:

• Hyperproliferation in Lung Cancer: The consistent and significant upregulation of core cell cycle activators and DNA replication machinery components (e.g., MCM genes like MCM4, MCM7, MCM3; CCNB1 for M-phase entry; CDK4, CDK7 for cell cycle progression; E2F1 as a master transcriptional regulator of proliferation; BUB3, WEE1, ANAPC1, MAD2L2 involved in mitotic regulation) is a hallmark of cancer. This indicates an increased fraction of cells actively engaged in the cell cycle, driving uncontrolled proliferation in both early and advanced lung tumors [1]. The escalating expression levels of several proliferation markers from early to advanced tumor stages suggest an exacerbation of proliferative activity as the disease progresses.

Compromised Cell Cycle Checkpoints and Tumor Suppression:

• The downregulation of GADD45B (Growth Arrest and DNA Damage-inducible protein beta) in tumor cells is biologically significant. GADD45B is involved in cell cycle arrest, DNA repair, and apoptosis [2]. Its reduced expression can compromise these protective mechanisms, allowing cells with DNA damage to continue proliferating, a key feature of genomic instability in cancer.
• The patterns for classic tumor suppressors like RB1, TP53, and SMAD4 are noteworthy. While their functional inactivation (often via mutation or deletion) is critical in cancer, their mRNA expression levels shown here are not consistently downregulated. For TP53 and SMAD4, observed upregulation in early tumor stages might reflect cellular stress responses, compensatory mechanisms, or in the case of TP53, the accumulation of stable mutant protein, which can be transcriptionally active but functionally impaired [3, 4].

Dysregulation of Ubiquitin-Proteasome System and Signaling:

• CUL1 (Cullin 1), a scaffold protein for SCF ubiquitin ligase complexes involved in cell cycle regulation, shows downregulation in advanced tumors. The functional consequence of CUL1 dysregulation depends on the specific substrates, but it can lead to stabilization of oncoproteins and promote cell division [5].
• MDM2 (Mouse Double Minute 2 Homolog) is a negative regulator of TP53, targeting it for degradation. Its upregulation in both tumor stages suggests an active mechanism to suppress p53 activity, thereby promoting cell survival and proliferation [6].
• TGFB1 (Transforming Growth Factor Beta 1) is upregulated in both tumor stages. While TGF-β signaling can have tumor-suppressive effects in early stages, it often switches to a pro-tumorigenic role in advanced cancers, promoting processes like epithelial-mesenchymal transition (EMT), angiogenesis, and immunosuppression [7].

Clinical or Translational Implications

• Biomarkers for Diagnosis and Prognosis: The consistently upregulated cell cycle genes (e.g., MCM4, MCM7, CCNB1, CDK4, CDK7, E2F1) represent promising biomarkers for detecting lung cancer epithelial cells and potentially for assessing disease aggressiveness or stage. Higher expression levels could correlate with faster tumor growth and poorer prognosis.

Therapeutic Targets:

• The significant upregulation of CDK4 and CDK7 in tumor cells highlights Cyclin-Dependent Kinases as potential therapeutic targets in lung cancer. CDK inhibitors, such as CDK4/6 inhibitors (e.g., Palbociclib, Ribociclib), are already established treatments for other cancers (e.g., breast cancer) and could be explored for lung cancer.
• The consistent upregulation of MDM2 suggests that MDM2 inhibitors, which aim to reactivate wild-type p53, could be a therapeutic avenue for lung cancers retaining functional p53.
• Targeting DNA replication components like MCM proteins might also be considered, though specificity and toxicity to normal proliferating cells would be a challenge.

• Understanding Disease Progression: The distinct expression profiles between early and advanced tumors (e.g., the progressive increase in MCM genes or the complex patterns of RB1/TP53/SMAD4) offer insights into the molecular drivers of tumor evolution. This knowledge can contribute to tailoring treatment strategies based on tumor stage and molecular characteristics, and potentially identify patients at risk of rapid progression.

References

1. Hallmarks of Cancer: https://pubmed.ncbi.nlm.nih.gov/?term=Hanahan+Weinberg+hallmarks+of+cancer
2. GADD45B Function: https://www.genecards.org/cgi-bin/carddisp.pl?gene=GADD45B
3. TP53 in Cancer: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TP53
4. SMAD4 in Cancer: https://www.genecards.org/cgi-bin/carddisp.pl?gene=SMAD4
5. CUL1 Function: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CUL1
6. MDM2 Function: https://www.genecards.org/cgi-bin/carddisp.pl?gene=MDM2
7. TGFB1 in Cancer: https://pubmed.ncbi.nlm.nih.gov/?term=TGFB1+lung+cancer+dual+role

20. Gene Ontology Analysis of Lung Epithelial Cells Across Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results, specifically Gene Set Analysis (GSA), for Lung Epithelial cells. The analysis was performed on up-regulated differentially expressed genes (DEGs) in various conditions compared to a reference 'Normal' state. Four distinct comparisons are examined:

1. Diploid vs. Normal: Comparing lung epithelial cells identified as diploid against normal lung epithelial cells.
2. Normal vs. others: Comparing normal lung epithelial cells against all other cell conditions (Tumor(adv), Tumor(early), Diploid). This highlights pathways characteristic of healthy tissue.
3. Tumor(adv) vs. Normal: Comparing advanced-stage tumor lung epithelial cells against normal lung epithelial cells.
4. Tumor(early) vs. Normal: Comparing early-stage tumor lung epithelial cells against normal lung epithelial cells.

The results are displayed as bar plots, where terms are ranked by their statistical significance (-log(p-val) and -log(q-val)).

Visual Summary

The four bar plots illustrate distinct patterns of pathway enrichment across different conditions of Lung Epithelial cells. Each plot ranks GO terms based on the negative logarithm of their p-value and q-value (FDR-adjusted p-value) for up-regulated genes.

1. GSA for Lung Epithelial cell: Diploid_vs_Normal: This plot shows enrichment for "Coronavirus disease," "Ribosome," "Glycolysis / Gluconeogenesis," "Glutathione metabolism," and "Protein processing in endoplasmic reticulum" among the top terms. The -log(p-val) values generally range up to 3.5, and -log(q-val) values are relatively low, indicating moderate significance.
2. GSA for Lung Epithelial cell: Normal_vs_others: This plot, contrasting normal cells against all others, shows "Phagosome," "PPAR signaling pathway," "Human T-cell leukemia virus 1 infection," "Type I diabetes mellitus," and "Allograft rejection" as leading terms. The -log(p-val) values reach up to 4.5, with corresponding positive -log(q-val) values, suggesting pathways enriched in the normal state.
3. GSA for Lung Epithelial cell: Tumor(adv)_vs_Normal: This comparison reveals highly significant enrichment for "Ribosome," "Spliceosome," "Pathways of neurodegeneration," "Coronavirus disease," "Huntington disease," "Parkinson disease," "RNA transport," "Alzheimer disease," and "Proteasome." The -log(p-val) and -log(q-val) scales are notably higher (up to 20 for p-val, 17 for q-val), indicating extremely strong statistical significance for these pathways in advanced tumor cells.
4. GSA for Lung Epithelial cell: Tumor(early)_vs_Normal: Similar to the advanced tumor state, this plot also shows "Ribosome," "Spliceosome," "Salmonella infection," "Protein processing in endoplasmic reticulum," and several neurodegenerative disease-related pathways at the top. The significance levels (-log(p-val) up to 20, -log(q-val) up to 17) are comparable to the advanced tumor condition, suggesting these alterations emerge early in tumorigenesis.

Biological Interpretation

The Gene Ontology analysis provides critical insights into the functional shifts within Lung Epithelial cells during different stages of lung cancer.

Hallmarks of Cancer Metabolism and Proliferation

• Diploid vs. Normal: While "Diploid" cells are not necessarily cancerous, the comparison to strictly "Normal" lung epithelial cells reveals early signs of metabolic perturbation. Pathways like "Glycolysis / Gluconeogenesis," "Central carbon metabolism in cancer," and "HIF-1 signaling pathway" are enriched. This suggests that even diploid cells within a tumor-bearing context or early transformed cells might undergo metabolic reprogramming, a known hallmark of cancer PubMed search: "Warburg effect lung cancer". "Protein processing in endoplasmic reticulum" and "Glutathione metabolism" also indicate increased cellular stress and antioxidant responses.
• Tumor (early & adv) vs. Normal: A striking finding across both early and advanced tumor conditions is the profound enrichment of pathways related to protein synthesis, processing, and degradation. "Ribosome," "Spliceosome," "Protein processing in endoplasmic reticulum," "Proteasome," and "Ubiquitin mediated proteolysis" are highly up-regulated. This collective activation points to a massive increase in cellular machinery dedicated to protein production and turnover, which is essential for rapid cell division, biomass accumulation, and adaptation to the oncogenic state in cancer cells PubMed search: "Ribosome biogenesis cancer". The consistency of these pathways from early to advanced stages underscores their fundamental role in lung cancer initiation and progression.

Immune Evasion and Inflammation

• Normal vs. others: The enrichment of "Phagosome," "PPAR signaling pathway," and "Antigen processing and presentation" in normal lung epithelial cells suggests robust immune surveillance, cellular housekeeping, and inflammatory regulation in healthy tissue. The PPAR pathway, in particular, is involved in lipid metabolism and anti-inflammatory responses GeneCards: PPARG. The suppression or alteration of these pathways in tumor cells (as they are less enriched in the "others" group compared to normal) could contribute to immune evasion and a pro-tumorigenic inflammatory environment.
• Infection-related pathways: "Salmonella infection," "Influenza A," and "Coronavirus disease" appear in multiple comparisons, particularly in tumor conditions. While these might reflect actual infections, they more broadly indicate the activation of innate immune responses and stress pathways, which can be manipulated by cancer cells or signify chronic inflammation that promotes tumorigenesis PubMed search: "infection inflammation cancer link lung".

Unanticipated Overlap with Neurodegenerative Disease Pathways

• A notable and intriguing observation is the strong enrichment of "Pathways of neurodegeneration," "Huntington disease," "Parkinson disease," and "Alzheimer disease" in both early and advanced tumor cells compared to normal. While these are typically associated with neurological disorders, the underlying cellular mechanisms often involve protein misfolding, aggregation, mitochondrial dysfunction, and endoplasmic reticulum stress PubMed search: "protein misfolding cancer neurodegeneration". The pronounced activation of these pathways in lung cancer cells suggests shared cellular stress responses or disruptions in protein homeostasis, which might be crucial for tumor cell survival and adaptation.

Clinical or Translational Implications

The GSA results highlight several biologically significant pathways with potential clinical relevance for lung cancer:

1. Therapeutic Targeting of Core Machinery: The consistent and highly significant up-regulation of "Ribosome," "Spliceosome," "Protein processing in endoplasmic reticulum," and "Proteasome" in both early and advanced tumor cells suggests that targeting these fundamental cellular processes could be effective therapeutic strategies. Inhibitors of proteasome (e.g., bortezomib in multiple myeloma) or spliceosome modulators are already in clinical use or under investigation, offering avenues for repurposing or developing novel agents for lung cancer.
2. Metabolic Reprogramming as a Target: The enrichment of "Glycolysis / Gluconeogenesis" and "HIF-1 signaling pathway" in diploid cells compared to normal suggests that metabolic vulnerabilities emerge early. Targeting tumor metabolism, such as glycolysis inhibition, could be a strategy for early intervention or prevention in high-risk individuals.
3. Understanding Immune Context: The distinct pathways enriched in normal cells (e.g., PPAR signaling, antigen processing) underscore the importance of maintaining or restoring anti-tumor immunity. Strategies that enhance antigen presentation or modulate inflammatory pathways could improve immunotherapy responses.
4. Novel Insights from Neurodegenerative Pathways: The unexpected enrichment of neurodegenerative disease pathways warrants further investigation. This could potentially uncover shared molecular mechanisms that contribute to cancer cell resilience or identify existing drugs for neurodegenerative diseases that could be repurposed for lung cancer, based on shared targets related to protein quality control or cellular stress.

21. Gene Set Enrichment Analysis of Lung Cancer Microenvironment

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results visualized as a dot plot. The analysis compares gene expression profiles across various cell types and conditions found in lung tissue, with all comparisons made against a 'Normal' reference condition, as indicated by the plot title and compute_cfg. The plot highlights biological pathways and gene sets that are significantly upregulated (positive Normalized Enrichment Score, NES, colored red) or downregulated (negative NES, colored blue). The size of each dot reflects the statistical significance of the enrichment, represented by -log(P). This comprehensive view allows for the identification of cell-type-specific and condition-dependent molecular alterations in the context of Lung Cancer.

Visual Summary

The dot plot reveals a complex landscape of pathway dysregulation across different cell types and tumor stages in lung cancer.

• Widespread Pathway Dysregulation in Tumor Conditions: A striking observation is the pervasive enrichment (large red dots) of numerous cancer-associated and metabolic pathways across multiple cell types in both 'Tumor (early)' and 'Tumor (adv)' conditions compared to 'Normal'.
• Lung Epithelial Cells as the Tumor Origin: Lung Epithelial cells, identified as the tumor-origin cell type, exhibit the most profound and consistent pathway alterations. Pathways related to cancer hallmarks such as "Non-small cell lung cancer", "PI3K-Akt signaling pathway", "MAPK signaling pathway", "HIF-1 signaling pathway", "Wnt signaling pathway", and "Notch signaling pathway" are highly enriched in both early and advanced tumor stages, as well as in 'Diploid' cells compared to 'Normal'. Metabolic reprogramming pathways like "Glycolysis / Gluconeogenesis", "Oxidative phosphorylation", and "Pentose phosphate pathway" are also strongly upregulated.
• Immune Cell Dysregulation: Immune cells (Macrophages, T cells, Dendritic cells, NK cells, B cells) show significant pathway changes, indicative of their active involvement in the tumor microenvironment (TME). "PD-L1 expression and PD-1 checkpoint pathway in cancer" is notably enriched in T cells (CD8+ and CD4+), Macrophages, and even in tumor-origin Lung Epithelial cells, suggesting immune evasion mechanisms. Inflammatory and immune signaling pathways such as "NF-kappa B signaling pathway", "Cytokine-cytokine receptor interaction", and "Toll-like receptor signaling pathway" are frequently enriched in Macrophages and Dendritic cells.
• Stromal Cell Activation: Fibroblasts and Endothelial cells also exhibit activation of pro-tumorigenic pathways. Fibroblasts show enrichment in "HIF-1 signaling pathway", "PI3K-Akt signaling pathway", and "Proteoglycans in cancer", consistent with their transformation into cancer-associated fibroblasts (CAFs). Endothelial cells show strong enrichment in "VEGF signaling pathway" and "HIF-1 signaling pathway", reflecting active angiogenesis.
• "Diploid" Tumor Cells Show Cancer Pathways: Intriguingly, "Lung Epithelial cell: Diploid_vs_Normal" shows significant enrichment for many cancer-related pathways. This suggests that even epithelial cells within the tumor environment that are classified as diploid already exhibit molecular signatures of cancer, potentially representing early transformed cells or cells undergoing non-aneuploid genetic changes.
• "Normal_vs_others" Profile: The "Normal_vs_others" columns (e.g., "B cell: Normal_vs_others") display patterns that are largely inverse to those seen in tumor conditions for the same cell type (more blue dots where tumor conditions have red, and vice versa). This indicates pathways that are characteristic of the healthy state and are suppressed or altered in the presence of tumor cells.
• Less Consistently Suppressed Pathways: Few pathways are consistently suppressed (blue dots) across many cell types and conditions, with "Regulation of lipolysis in adipocytes" and "Adrenergic signaling in cardiomyocytes" being notable but less directly relevant to lung cancer.

Biological Interpretation

The GSEA results provide a detailed molecular blueprint of the lung cancer microenvironment, highlighting crucial biological processes involved in tumor initiation, progression, and interaction with surrounding cells.

• Oncogenic Signaling Driving Tumor Growth: The consistent upregulation of key signaling pathways (PI3K-Akt, MAPK, Wnt, HIF-1, Notch) in tumor-origin Lung Epithelial cells underscores their central role in promoting uncontrolled proliferation, survival, and adaptation to the harsh TME. These pathways are frequently hyperactivated in various cancers, including Non-Small Cell Lung Cancer (NSCLC) GeneCards: PI3K-Akt Pathway.
• Metabolic Reprogramming as a Cancer Hallmark: The enrichment of "Glycolysis / Gluconeogenesis", "Oxidative phosphorylation", and "Pentose phosphate pathway" points to a profound metabolic shift in tumor cells, characteristic of the Warburg effect (increased aerobic glycolysis) and enhanced anabolism to support rapid cell division PubMed: Cancer Metabolism. This reprogramming is also observed in stromal and immune cells, indicating a metabolic rewiring of the entire TME.
• Immune Evasion via Checkpoint Pathways: The prominent enrichment of "PD-L1 expression and PD-1 checkpoint pathway in cancer" in both tumor cells and various immune subsets (T cells, Macrophages) strongly suggests active immune evasion mechanisms. Tumor cells upregulate PD-L1 to suppress anti-tumor T cell responses, leading to T cell exhaustion and creating an immunosuppressive environment UniProt: PD-L1.
• Inflammation and TME Remodeling: The widespread activation of cytokine, chemokine, NF-kappa B, and Toll-like receptor signaling pathways in immune cells (especially Macrophages and Dendritic cells) signifies a highly inflamed TME. This chronic inflammation can paradoxically fuel tumor growth, angiogenesis, and metastasis by releasing pro-tumorigenic factors and modulating immune responses towards an immunosuppressive phenotype (e.g., M2-like macrophages) PubMed: Inflammation and Cancer.
• Stromal Contribution to Tumor Progression: The activation of Fibroblasts into CAFs and Endothelial cells in angiogenesis pathways (VEGF, HIF-1) demonstrates the critical supportive role of the stroma in tumor development, providing structural support, growth factors, and fostering a pro-tumorigenic niche.
• Early Oncogenic Changes in Diploid Cells: The observation that 'Diploid' Lung Epithelial cells within the tumor context already exhibit significant enrichment of cancer-related pathways suggests that oncogenic transformation can precede detectable aneuploidy or that these cells are strongly influenced by the tumor microenvironment, indicating early molecular changes even in cells without gross chromosomal abnormalities.

Clinical or Translational Implications

The detailed pathway analysis provides valuable insights with potential clinical and translational impact for Lung Cancer.

• Targeted Therapies: The consistently enriched oncogenic signaling pathways (e.g., PI3K-Akt, MAPK, Wnt) represent established therapeutic targets. Inhibitors against these pathways, either alone or in combination with other treatments, could be effective.
• Immunotherapy Rationalization: The strong upregulation of the "PD-L1 expression and PD-1 checkpoint pathway in cancer" in multiple cell types reinforces the clinical utility of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) in lung cancer. Identifying which cell types primarily drive this expression could guide more refined immunotherapeutic strategies.
• Metabolic Intervention: The distinct metabolic reprogramming observed in tumor cells suggests potential vulnerabilities that could be targeted by metabolic inhibitors, potentially starving cancer cells or sensitizing them to conventional therapies.
• Biomarker Discovery: Specific genes within the highly enriched pathways (e.g., those contributing to the "Non-small cell lung cancer" pathway or checkpoint pathways) could serve as diagnostic, prognostic, or predictive biomarkers for patient stratification and treatment response monitoring.
• Understanding Tumor Heterogeneity: The cell-type-specific pathway enrichment underscores the cellular heterogeneity of the TME. Acknowledging that different cell types contribute uniquely to tumor progression implies that multi-modal or combination therapies targeting various components of the TME might be more effective than single-target approaches.
• Early Detection and Prevention: The observation of cancer-related pathway enrichment in diploid lung epithelial cells suggests the potential for developing early detection strategies by identifying these molecular changes even before overt malignancy or aneuploidy is established.

22. Discussion

The single-cell RNA sequencing analysis of human lung tissue provides an unprecedented resolution into the intricate cellular and molecular changes underlying lung cancer progression. A central finding is the robust identification of malignant lung epithelial cells, primarily originating from alveolar epithelial cells, characterized by extensive aneuploidy and pervasive genomic instability, including recurrent amplifications of key oncogenes such as EGFR and ERBB2 (HER2). These genomic alterations are evident from early disease stages and intensify with progression, confirming their foundational role in oncogenesis.

The tumor microenvironment (TME) undergoes dramatic remodeling, profoundly impacting both immune and stromal compartments. A critical shift towards immunosuppression is observed with the early and sustained enrichment of regulatory T cells (Tregs), which significantly increase in both early and advanced tumor stages. Concurrently, a progressive decrease in Natural Killer (NK) cells and ILC2s highlights a diminished innate anti-tumor response. Macrophages exhibit a striking phenotypic switch, with a significant and progressive increase in pro-tumorigenic M2B macrophage subsets and a decrease in M2A subsets, further contributing to an immunosuppressive and pro-growth milieu. These immune cell dynamics suggest a complex interplay where the host immune system attempts to respond initially but is progressively subverted and exhausted by the advancing tumor.

Cell-cell communication analysis reveals active and dysregulated crosstalk between tumor-origin lung epithelial cells and their TME constituents. Prominent interactions include autocrine/paracrine EGFR signaling among tumor cells and with macrophages and fibroblasts, which drives proliferation and TME conditioning. TGF-beta signaling also emerges as a crucial mediator of tumor-stromal-immune interactions, promoting epithelial-mesenchymal transition (EMT) and fostering an immunosuppressive and fibrotic niche. Notably, tumor cells actively engage in immune evasion by secreting immunosuppressive mediators like Prostaglandin E2 (PGE2) and Retinoic Acid, which modulate T cell and B cell functions. Angiogenesis is robustly supported through VEGF family interactions with endothelial cells, indicating active vascular remodeling.

Gene Ontology and Gene Set Enrichment Analysis further illuminate the molecular underpinnings of these cellular changes. Tumor-origin lung epithelial cells universally exhibit massive upregulation of machinery for protein synthesis, processing, and degradation (ribosomes, spliceosomes, proteasomes), indicative of their heightened proliferative state. Unexpectedly, these cells also show significant enrichment of pathways associated with neurodegenerative diseases, suggesting shared cellular stress responses or protein quality control disruptions critical for tumor cell adaptation. The observation that even diploid lung epithelial cells within the tumor context display significant enrichment of cancer-related pathways suggests that oncogenic transformation can precede overt aneuploidy, or these cells are rapidly conditioned by the evolving tumor microenvironment.

In contrast to commonly observed patterns in some 'hot' tumors, the TME here suggests a landscape trending towards immune exclusion or exhaustion in later stages, characterized by a relative reduction of certain helper T cell subsets from early to advanced disease alongside persistent NK cell suppression. The detailed identification of surfaceome markers across malignant epithelial cells, macrophages, fibroblasts, and CD4+ T cells provides a rich molecular landscape for identifying actionable therapeutic targets, ranging from well-established oncogenic drivers to novel modulators of tumor-microenvironment interactions.

Hypotheses:

1. Aneuploidy drives early immune evasion: The early onset and progressive increase of aneuploidy in lung epithelial cells directly contribute to the observed shifts in immune cell populations (e.g., Treg enrichment, NK cell suppression) by altering antigen presentation or secreting immunosuppressive factors.
2. Macrophage polarization is a primary determinant of tumor aggressiveness: The progressive increase in pro-tumorigenic M2B macrophages, coupled with the decline of M2A macrophages, directly correlates with tumor progression and predicts a more aggressive disease course in lung cancer.
3. Co-targeting EGFR and TME-modulating pathways will overcome resistance: Given the prevalent EGFR amplifications and the active EGFR signaling in tumor cells and stromal cells, combining EGFR inhibitors with agents that target specific TME components (e.g., FAP, CSF1R, TGF-beta, or PGE2 pathways) will overcome adaptive resistance mechanisms and enhance anti-tumor responses.
4. Neurodegenerative disease pathways represent novel tumor vulnerabilities: The strong and unexpected enrichment of neurodegenerative disease-related pathways in tumor-origin lung epithelial cells indicates shared mechanisms of cellular stress and protein dyshomeostasis that could be exploited therapeutically, potentially through drug repurposing.

Potential therapeutic targets:

1. EGFR (Epidermal Growth Factor Receptor): Highly and broadly expressed in tumor-origin lung epithelial cells, often amplified (7p13:7q11.23 region), and involved in extensive autocrine/paracrine signaling with TME components (macrophages, fibroblasts), driving proliferation, survival, and TME remodeling. Evidence: Recurrent amplification in tumor-origin cells (Section 4, Image 5). Robustly upregulated in tumor epithelial cells (Section 15, Image 18). Involved in significant cell-cell interactions (EREG_EGFR, AREG_EGFR, HBEGF_EGFR) with tumor cells, macrophages, and fibroblasts (Section 14, Image 17). GSEA confirms activation of MAPK and PI3K-Akt pathways (Section 21, Image 27). The dataset context also notes 'EGFR_mutation' metadata. Validation: Clinical trials with EGFR TKIs (Gefitinib, Erlotinib, Osimertinib) are well-established. Further validation could involve combination therapies targeting EGFR and TME components, e.g., co-targeting EGFR with anti-fibrotic agents in models with high fibroblast activity.
2. ERBB2 (HER2): Recurrently amplified (17q21.1:17q21.2 region) and overexpressed in a subset of tumor-origin lung epithelial cells, functioning as a co-receptor to enhance pro-survival and pro-proliferative signaling pathways. Evidence: Section 4 shows recurrent amplification (Image 5). Section 15 shows increased expression in a distinct subset of tumor samples (Image 18). GSEA indicates activated PI3K-Akt pathway (Section 21), consistent with ERBB2 signaling. Validation: Clinical trials are ongoing with HER2-targeted therapies like trastuzumab deruxtecan (T-DXd) for HER2-mutant NSCLC. Further validation could involve patient stratification based on ERBB2 amplification status for specific HER2-directed therapies and assessing clinical outcomes.
3. CSF1R (Colony Stimulating Factor 1 Receptor): Highly expressed on tumor-associated macrophages (TAMs) in early and advanced tumor conditions, playing a critical role in their recruitment, survival, and pro-tumorigenic polarization within the TME. Targeting CSF1R can deplete or reprogram TAMs. Evidence: Section 16 (Image 19) clearly shows CSF1R as a marker with strong enrichment in tumor-associated macrophages. Section 9 and 10 confirm the shift towards M2-like pro-tumorigenic macrophages (M2B, M2C) in tumor conditions, which are often sustained by CSF1R signaling. Validation: Preclinical studies in lung cancer models with CSF1R inhibitors (e.g., Pexidartinib) to assess TAM depletion/reprogramming and anti-tumor efficacy, especially in combination with immune checkpoint inhibitors. Clinical trials are evaluating CSF1R inhibitors in various cancers.
4. FAP (Fibroblast Activation Protein Alpha): A canonical marker of cancer-associated fibroblasts (CAFs), highly expressed in early tumor-associated fibroblasts but minimally in normal tissues. FAP+ CAFs promote tumor growth, invasion, and metastasis by remodeling the ECM and creating an immunosuppressive environment. Evidence: Section 17 (Image 20) demonstrates strong and prevalent expression of FAP in fibroblasts from early tumor samples, absent in normal. Section 13 and 14 highlight extensive collagen-integrin interactions involving fibroblasts and tumor cells, which FAP contributes to by ECM remodeling. Validation: Preclinical testing of FAP-targeted therapies (e.g., FAP-specific antibodies, CAR T-cells, radioconjugates) in lung cancer models to evaluate CAF depletion, ECM normalization, and enhanced anti-tumor immunity.
5. TGF-beta Pathway (e.g., TGFB1, TGFbeta_receptor1/2): Active autocrine/paracrine signaling from aneuploid lung epithelial cells to themselves and with TME cells (macrophages, fibroblasts) drives tumor growth, EMT, fibrosis, and immune suppression. TGF-beta pathway components are upregulated in tumor epithelial cells. Evidence: Section 13 and 14 highlight multiple significant TGF-beta-mediated cell-cell interactions: TGFB1_TGFbeta_receptor1 (autocrine in tumor cells), TGFB1_TGFbeta_receptor2 (Mac to tumor cells), TGFB3_TGFBR3 (tumor cells to fibroblasts) (Images 16, 17). Section 19 shows upregulation of TGFB1 in tumor epithelial cells (Image 22). GSEA confirms activation of TGF-beta signaling pathways (Section 21). Validation: Clinical trials with TGF-beta inhibitors (e.g., Galunisertib, Fresolimumab) in lung cancer, often in combination with immune checkpoint inhibitors, to reverse immunosuppression and desmoplasia.
6. ICOS (CD278): An inducible co-stimulatory molecule highly expressed on tumor-associated CD4+ T cells in both early and advanced stages. It plays a complex role, promoting T cell activation but also influencing immunosuppressive Tregs. Modulating ICOS can enhance anti-tumor T cell responses. Evidence: Section 18 (Image 21) shows ICOS as an upregulated marker in tumor-associated CD4+ T cells. Section 8 details the increase in several helper T cell subsets and Tregs in early tumor stages, which can express ICOS. Validation: Clinical trials with ICOS agonistic antibodies (e.g., JTX-2011) to enhance anti-tumor T cell immunity in lung cancer patients, potentially combined with other immunotherapies. Further studies to dissect its role in effector vs. regulatory T cells in the TME.

Follow-up validation ideas:

1. Flow cytometry/Immunostaining: Quantify the proportions and activation states of T cell subsets (Tregs, NK cells, helper T cells) and macrophage subsets (M1/M2B/M2A) in a larger cohort of lung cancer patients at different stages and in normal tissues using multi-parameter flow cytometry or spatial transcriptomics combined with immunostaining to validate population shifts and their spatial localization.
2. CRISPR/shRNA perturbation assays: In vitro and in vivo models of lung cancer (cell lines, patient-derived organoids, PDX models) to knock down or overexpress key genes implicated in specific cell-cell interactions (e.g., PTGES3, ALDH1A1, NRP1, COL1A1) in tumor cells or TME cells, followed by functional assays (proliferation, invasion, immune cell co-culture, angiogenesis).
3. Drug sensitivity screens: Test candidate therapeutic agents (e.g., EGFR TKIs, CSF1R inhibitors, FAP inhibitors, TGF-beta pathway blockers, EP2/EP4 receptor antagonists) individually and in combinations on lung cancer cell lines and co-culture systems representing the identified TME interactions, followed by dose-response and synergy analyses.
4. Spatial Transcriptomics/Proteomics: Apply spatial transcriptomics or high-plex spatial proteomics (e.g., CODEX, IMC) to lung cancer tissue sections to confirm the co-localization and spatial interactions of specific cell types (e.g., aneuploid epithelial cells, M2B macrophages, FAP+ fibroblasts) and their surface markers (e.g., CSF1R, FAP, EGFR, MUC4) within the tumor microenvironment.
5. Genomic/Clinical Cohort Validation: Validate recurrent CNVs (EGFR, ERBB2) and their correlation with patient outcomes, treatment response, and specific histological subtypes using larger independent lung cancer patient cohorts with matched genomic and clinical data (e.g., TCGA, other single-cell or bulk-seq datasets).
6. Mechanistic studies of neurodegenerative pathways: Conduct biochemical and cell biology experiments to investigate the functional consequences of activated neurodegenerative disease pathways (e.g., protein aggregation, ER stress, mitochondrial dysfunction) in lung cancer cells and how their modulation impacts tumor cell survival, proliferation, and drug sensitivity.

Limitations:

This single-cell analysis provides comprehensive insights into lung cancer; however, certain limitations should be noted. The dataset primarily relies on transcriptional measurements, which may not fully capture post-translational modifications, protein activity, or cell-state dynamics. The inference of CNVs from RNA-seq data, while robust, is an approximation and would benefit from orthogonal genomic validation (e.g., WGS, FISH). While numerous cell-cell interactions are predicted, these are computational inferences based on ligand-receptor expression and require experimental validation to confirm functional significance. The cross-sectional nature of the data does not allow for direct observation of dynamic processes of tumor evolution or immune cell fate decisions in individual patients over time. Finally, the observed patient-specific heterogeneity, while biologically informative, implies that generalized therapeutic strategies may require further stratification based on individual tumor microenvironment characteristics.

23. Query List

1. Show and save UMAPs for condition, sample, celltype_major, celltype_minor, ploidy_dec, and celltype_subset in two columns.
2. Show major cell type scores on UMAP and save the result.
3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
4. Select Lung Epithelial cells (tumor-origin), show a CNV heatmap grouped by sample together with a summary of regions with significantly amplified copy numbers, and save the results.
5. Show and save UMAPs of CNV patterns colored by celltype_major, celltype_minor, ploidy_dec, condition, and sample in two columns.
6. Show and save a population bar plot of celltype_minor.
7. Show and save a population bar plot of T cell subsets.
8. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
9. Show and save a population bar plot of macrophage subsets.
10. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
11. Select Lung Epithelial cells (tumor-origin), show their ploidy populations as a bar plot, and save the result.
12. Show and save cell-cell interaction patterns involving Lung Epithelial cells (tumor-origin), Fibroblast, Macrophage, T cell, B cell, Dendritic cell, and Endothelial cell. Select at most 80 cell-cell interactions per group.
13. Find cell-cell interactions involving Lung Epithelial cells (tumor-origin), major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
14. Find cell-cell interactions containing immune checkpoint and cell cycle pathway genes and involving Lung Epithelial cells (tumor-origin), major immune and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms, its potential as a therapeutic target, and relevant therapeutic agents.
15. Show marker expressions for Lung Epithelial cells (tumor-origin) in a dot plot, and save the result. Use only surfaceome markers, with at most 60 markers per condition. For the markers identified under each condition, distinguish between established therapeutic targets and less well-characterized markers with potential as therapeutic targets. For each marker, using the provided dataset context, describe the associated signaling pathways and mechanisms, relevant therapeutic agents, and supporting evidence.
16. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
17. Show marker expressions for Fibroblast in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
18. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways, the role of the corresponding cell type in the tumor microenvironment, the marker’s potential as a therapeutic target, relevant therapeutic agents, and other pertinent information.
19. Among cell cycle pathway genes, select those with statistically significant expression differences between conditions in Lung Epithelial cells (major disease-related cells), show box plots, and save the result. Set max_n_items_to_plot to 24 and choose ncols based on the total number of panels for an overall width-to-height ratio of approximately 2:3.
20. Show and save Gene Ontology (GSA) analysis results for Lung Epithelial cells (tumor-origin) as a bar plot.
21. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.